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8Abstract 
Background: The prevalence of Parkinson’s Disease (PD) in Norway is about 
100/100 000 inhabitants. For planning of health care needs and for research purposes, 
incidence figures are considered the more valuable information, but have in Norway 
not been available for PD. Earlier incidence studies have shown variable results, 
likely due to methodological differences. To improve comparability, research criteria 
for high quality incidence studies of PD have been proposed in 2003.  
PD is more frequent in men than women, but the underlying causes are not clear. As 
the difference does not persist throughout all studies and geographic areas, further 
evidence on the issue is needed, also concerning clinical disparities between genders.  
Non-motor symptoms have in the last two decades been increasingly recognized as 
important contributors to the clinical picture of PD, the disease burden and the quality 
of life of patients. Knowledge on the presence, severity and consequences of non-
motor symptoms, including autonomic and sensory disturbances, is best for mid-stage 
and advanced PD, but insufficient for the earliest disease stages. There are 
furthermore discussions as to whether motor or non-motor symptoms are the most 
important contributors to reduced quality of life in PD.   
Patients and methods: We followed proposed research criteria and aimed to recruit 
all cases of incident PD from the Norwegian counties Sogn og Fjordane, Hordaland, 
Rogaland and Aust-Agder, comprising a base-population of about 1 million 
inhabitants. Cases with probable PD were invited to further examinations and 
longitudinal follow-up. Motor symptoms, non-motor symptoms and quality of life 
were assessed soon after diagnosis in drug-naïve state, and one year and 3 years later. 
Results and conclusions: Based on 265 cases identified during 22 months and finally 
diagnosed as incident PD, the crude incidence of PD in Norway was estimated to 
13.7/100 000, corresponding to 12.6/100 000 when adapted to a European standard 
population. This figure is in line with other modern incidence studies in Europe, 
9although there is a persisting, considerable range of the presented incidence numbers 
(8.4-15.8/100 000). Further homogenization of the methodology for incidence studies 
may therefore be needed, but could be difficult to achieve. 
We confirmed an increased risk for PD in men with a male to female ratio of 1.58. 
Beside a slightly later onset in women clinical differences were lacking in our study. 
We could thus not provide supporting evidence for neuroprotective mechanisms in 
women that are effective after PD has become clinically overt. 
Autonomic and sensory symptoms and signs were very frequent in early, untreated 
PD. Most frequent were reduced olfaction (59%), urinary problems (47%), increased 
saliva/drooling (42%), constipation (39%) and sensory complaints (34%), all of which 
occurred significantly less frequent in controls matched for age and gender. Most 
patients (58%) were not impaired in their daily activities by any of these symptoms. 
Although health-related quality of life (HRQoL) was overall reduced in patients 
compared to controls already at diagnosis, the contribution of autonomic symptoms 
was small. The main predictors of reduced HRQoL were fatigue and depression, and 
to a minor degree also sensory complaints. The most important motor symptoms to 
affect HRQoL were impairment of gait and of the ability to conduct personal needs as 
eating, dressing, hygiene and to turn in bed. These issues have not been highlighted 
earlier, and should guide the focus of treating physicians to the here mentioned 
symptoms in the meeting with patients with very early PD.  
Our results further indicate that, overall, non-motor symptoms have more impact on 
HRQoL than motor symptoms, both at the time of diagnosis and three years later. As 
our patients were initially drug-naïve, this dominance seems to be independent of the 
often reported better recognition and treatment of motor vs. non-motor symptoms.   
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1. Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder primarily 
defined by movement disturbances which usually are asymmetric and include 
involuntary shaking (tremor), stiffness (rigidity), slowness and reduced amplitude of 
movements (bradykinesia), and frequently also disturbances of balance (postural 
instability). Beside the motor disturbances, a large variety of non-motor symptoms are 
observed in PD which range from autonomic, sensory and mood disturbances to 
impaired cognition and sleep. PD occurs mainly in individuals aged 60 years or older, 
but can also affect much younger people. Beside a minority of clearly inherited cases, 
the cause of Parkinson’s disease is not known. 
1.1 Historical background 
James Parkinson, an English surgeon, was in 1817 the first to describe the symptoms 
of the disease today named after him in his “Essay on the shaking palsy”1, which was 
based on the observation of six patients. Although he characterized the condition by 
its motor symptoms, he also recognized non-motor symptoms affecting autonomic 
function and sleep. In 1877, Jean-Martin Charcot in Paris improved the clinical 
description of the condition and honoured Parkinson’s work by introducing the term 
“maladie de Parkinson” (Parkinson’s disease). Although James Parkinson hoped his 
work would stimulate research on the pathophysiological background of the disorder,2  
it took until 1953 to identify characteristic neuropathological changes and cell loss in 
the substantia nigra as key-factors in PD.3  
At this time, there was no treatment available to reduce the symptoms of the disease 
and it led to death from the complications of immobility. In 1957, Arvid Carlsson 
demonstrated the reversibility of drug-induced parkinsonism in animals by 
administration of levodopa,4 and some years later, dopamine-depletion in the striatum 
of patients with PD was found.5 This led to the crucial trial of Birkmayer and 
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Hornykiewicz, who for the first time administered levodopa to patients with 
parkinsonism by injection, what induced dramatic, although transient improvement of 
motor function.6 In 1967, George Cotzias had optimized the treatment by stepwise 
and slow increase to higher doses, thus achieving pronounced symptom reduction and 
less side effects.7 Since then, treatment options have improved substantially, and 
many patients can achieve close to normal motoric functioning at least up to some 
years after the diagnosis of Parkinson’s disease is established. Side effects of 
levodopa, especially motor fluctuations, have stimulated the development of 
dopamine agonists with longer half-life, and beneficial effects of Bromocriptine were 
reported in 1974.8 Thermoelectric lesions of thalamic neurons were before and after 
the introduction of levodopa applied for effective tremor reduction. From the1990s, 
this was increasingly replaced by deep brain stimulation, which offers better control 
of effect and side effects in selected patients and includes further targets in the basal 
ganglia.9,10  
The large variety of non-motor symptoms associated with PD was widely neglected 
until the early 1990s, but has since achieved increasing attention. Cognitive, 
autonomic, sensory and sleep-related symptoms are now accepted as core features of 
the disease and recognized as major contributors to reduced quality of life in PD.11,12
Symptoms like olfactory dysfunction, constipation and REM sleep behaviour disorder 
(RBD) frequently antedate the manifestation of motor symptoms considerably, thus 
defining a period of pre-motor PD.13 In the first decade of the 21st century, PD-
specific rating scales have been developed or modified to cover also non-motor 
symptoms extensively.14-16  
In 1912, the German-American neurologist F.H. Lewy discovered protein-rich 
inclusions in brainstem neurons of patients with PD.17 These structures, today known 
as Lewy bodies, are still the histopathological hallmark of PD. When in 1997 the first 
mutation causing familial PD was discovered in the Į-synuclein gene, the content of  
Lewy bodies was short after identified as accumulations of the protein Į-synuclein.18
This initiated a fundamental improvement of the knowledge and understanding of the 
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pathophysiological mechanisms in PD. Based on the now possible immunostaining of 
Į-synuclein in Lewy bodies, Heiko Braak could develop a histopathological model of 
gradual spreading neuropathological changes from the brainstem to midbrain and 
cerebral structures.19 His model integrates the frequently observed initial appearance 
of selected non-motor symptoms, followed by the classical motor symptoms and in 
later stages by cognitive impairment due to cortical involvement. It does, however, 
not explain the whole variety of observed clinical courses and pathological findings. 
Today, more than 20 mutations are known that are associated with monogenic 
familiar PD or an increased risk to develop the disease,20 and knowledge about the 
neuropathology and pathophysiology of PD and its symptoms has improved 
considerably.21,22 However, while about 10-20% of cases of PD may possibly be 
explained by monogenetic mechanisms, the essential disease-causing mechanisms for 
the remaining 80-90% of cases remain unknown even today.  
1.2 Etiology and pathophysiology 
1.2.1 Basal ganglia 
Movements are finally initiated by signals from the motor cortex, which projects via 
the pyramidal tract to lower motor-neurons in the brainstem and medulla, and further 
via cranial or peripheral nerves directly to the executing muscles. Movements are 
frequently complex themselves, but do also interact with external and internal 
circumstances mediated by sensory-motor, sensory, emotional and cognitive signals. 
The role of the basal ganglia is to facilitate complex and automated movements and 
adapt them to current and memorized multifactorial circumstances. 
The basal ganglia are subcortical nuclei or neuron-groups composing a functional 
network. They include the striatum (caudate nucleus and putamen), globus pallidus 
externus (GPe) and internus (GPi), substantia nigra (with pars compacta, SNc, and 
pars reticulata, SNr) and nucleus subthalamicus (STN). Cortical input to the striatum 
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is processed in this network and the output from GPi and SNr is facilitating or 
inhibitory for cortical activity. The superior objective is to facilitate wanted and 
inhibit unwanted movements.23,24 Beside a circuit for modification of motor activity, 
the basal ganglia comprise also circuits to process oculo-motor, associative/cognitive 
and limbic signals.25  
The hypokinetic movement disturbances in PD may be explained by a model of the 
functional connectivity within the basal ganglia, proposed in 1990.24 Dopaminergic 
nigro-striatal projections from the SNc are excitatory for a direct pathway via type 1 
dopaminergic (D1)-receptors, and inhibitory for an indirect pathway, via D2 
receptors.26 Reduced activity of nigro-striatal neurons to both pathways leads to 
increased GPi/SNr activity, which inhibits thalamo-cortical excitatory feedback, 
meaning movement is rather inhibited than facilitated. 
In early PD, overactivity of the basal ganglia can compensate for the beginning loss of 
nigro-striatal dopaminergic activity. With further progression, the balance is deranged 
and the inhibitory output increases.27 It is estimated that motor symptoms emerge 
when about 60% of dopaminergic neurons in the SNc and 80% of striatal 
dopaminergic activity are lost.28
However, basal ganglia function is today regarded as much more complex, including 
feedback mechanisms, multiple interconnections between several ganglia, and 
modulation of firing patterns in response to reduced dopaminergic activity – as 
opposed to changed net activity.29
1.2.2 Neuropathology 
Degeneration of dopaminergic neurons in the substantia nigra pars compacta is the 
central pathological mechanism in PD. This process is usually associated with the 
occurrence of eosinophilic, Į-synuclein containing protein-aggregations called Lewy 
bodies and Lewy neurites, the histopathological hallmark of PD.30,31 However, 
beyond the substantia nigra, neuropathological changes are also observed in other 
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brainstem nuclei (nucleus basalis of Meynert, dorsal motor nucleus of the vagal nerve, 
locus coeruleus, raphe nucleus), nucleus Edinger-Westphal in the midbrain, striatum, 
cerebral cortex and the olfactory bulb, as well as parts of the peripheral nervous 
system and several organs like skin, retina, submandibular glands and the heart.22 This 
may explain the broad spectrum of non-motor symptoms associated with PD.  
Based on the dominating presence of Į-synuclein pathology, PD is classified as a 
synucleinopathy, together with Dementia with Lewy bodies (DLB), Multiple system 
atrophy (MSA) and Pure autonomic failure. Other neurodegenerative disorders with 
parkinsonian features like Alzheimer’s disease, Corticobasal degeneration and 
Progressive supranuclear palsy (PSP) are characterized by abnormal accumulation of 
tau-protein, and therefore grouped as tauopathies. Interestingly, both groups show 
some clinical and histopathological overlap, indicating shared pathophysiological 
mechanisms at least in a proportion of cases.32 Another typical pathological feature of 
Alzheimers-disease, ȕ-amyloid plaques, is also overlapping and frequently found in 
PD with dementia and Dementia with Lewy bodies.33
In PD, the pathognomonic Lewy bodies and Lewy neurites are localized in the 
cytoplasma of neuron bodies and neurites, respectively. More than eighty years after 
their initial description by Friedrich H. Lewy,17 the protein Į-synuclein, normally 
involved in synaptic membrane processes, was discovered as their main 
component.18,21 Abnormal accumulations of Į-synuclein occur as oligomers, 
protofibrils and fibrils, the latter accumulating further to Lewy neurites or Lewy 
bodies.34 Although associated with neuronal degeneration, Lewy bodies are not 
necessarily the cause of cell death. It has been suggested that Į-synuclein oligomers 
and protofibrils are cytotoxic, while the fibrillar aggregates may represent a protective 
cellular storage form which prevents from cell death until the load of abnormal 
proteins exceeds the storage capacity.34,35  
The primary structure responsible for the degeneration of unwanted proteins is the 
ubiquitin-proteasome system, which depends on mitochondrial energy-supply. Its 
failure and the resulting insufficient removal of pathologic proteins like Į-synuclein 
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are associated with neurodegeneration.36 Mitochondrial dysfunction has been linked 
to PD initially due to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin), an 
impurity in synthetic heroin which in the 1980s led to parkinsonian symptoms  in 
drug-addicts by destruction of dopaminergic neurons in the substantia nigra.37,38 After 
oxidation to MPP+, it accumulates in mitochondria and inhibits complex I, an 
essential part of the respiratory chain, and leads finally to toxic insult of the cell.39
Animal models of MPTP-induced parkinsonism have contributed enormously to the 
understanding of basal ganglia function, the pathogenesis of PD and to the 
development of treatment for PD. Mitochondrial dysfunction has further been linked 
to PD based on findings involving other complex I inhibitors like pesticides or certain 
herbs,40,41 reduced complex I activity found in substantia nigra and frontal cortex,42-44
several gene-mutations linked to mitochondrial function35,39 and increased oxidative 
stress.35,45
Also lysosomal dysfunction facilitates the PD-specific, pathological protein 
aggregations46 and mutations in the glucocerebrosidase gene, which encodes for a 
lysosomal enzyme, increase the risk for PD.47 Other factors that seem to be involved 
in the pathophysiology of PD are iron-accumulation, dopamine itself and 
neuromelanin, all of them being associated with increased oxidative stress and 
neurodegeneration.48,49
The observation that more severe symptoms in PD are associated with more 
widespread occurrence of Lewy bodies, while motor symptoms only become manifest 
when severe damage of the substantia nigra is already reached, motivated the German 
pathologist Heiko Braak to study a large series of cases with variable degree of Lewy 
body pathology, including cases without clinical symptoms of parkinsonism. In 2003, 
he published a hypothesis based on findings in 110 cases, suggesting a sequential 
development of Lewy pathology and corresponding degeneration:19  
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- In stage 1 and 2, the olfactory nucleus and bulb, medulla oblongata and pontine 
tegmentum are affected, including the nuclei of vagus, glossopharyngeus, 
raphe and coeruleus.  
- Only in stage 3, the midbrain is reached with pathology in the substantia nigra 
pars compacta.  
- In stage 4, lesions occur also in the basal prosencephalon and mesocortex.  
- In stage 5 and 6, increasing pathology of the neocortex is observed.  
With each stage, the severity of pathology in the affected structures increases.   
Figure 1: Progression of PD-related neuropathology as supposed by H. Braak et al. (2003).19
More intense color indicates earlier and more severe affection. (Copy from original publication) 
There has been substantial critic of this hypothesis, mainly based on a lack of a 
clinico-pathological correlation with respect to severity of parkinsonism, and the fact 
that cases with the two initial stages of Į-synucleinopathy did not show affection of 
the substantia nigra, which means it remains hypothetic to propose that these 
individuals would ޤ if not died ޤ have proceeded further according to the staging 
scheme or developed clinical PD.50 However, Braak’s hypothesis has shed a new light 
on the earliest stages of PD including the time when the disease is 
pathophysiologically established, but motor symptoms have not yet emerged, the 
premotor phase. It has long been recognized that some autonomic symptoms and 
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hyposmia are associated with PD already in the early stages51-53 or increase the risk to 
develop PD,54 and Braaks model may explain these phenomena in part by initial 
involvement of brainstem structures and the olfactory bulb. However, the model has 
limitations as the spinal cord and peripheral nervous system were not examined.19
The molecular mechanisms for the hypothesized spreading pathology as well as its 
initiation are not yet resolved. Braak and coworkers have suggested that the initial 
changes occur in the olfactory bulb and/or the gastrointestinal mucosa, induced by an 
exogenous, neurotropic, unknown biological agent. Centripetal axonal transmission to 
brainstem nuclei then would allow further spreading within the central nervous 
system – the dual-hit hypothesis.55-57 Based on a number of pathophysiological 
similarities it has hereupon been suggested that PD and other neurodegenerative 
disorders may be prion-like diseases. Essential in this context are protein-misfolding 
and intercellular transmission of the abnormal proteins,58 a mechanism suspected after 
Lewy-patholgy was identified in graft cells transplanted into the striatum of PD 
patients.59,60 There is, however, no evidence for infectious attitude in PD, and no clue 
of what could be the initiating pathogenic external agent. 
1.2.3 Etiology and risk factors 
Despite a small group of monogenic familial cases with PD or a parkinsonism at least 
in part resembling PD, there is no known single cause of PD. However, a number of 
factors have been identified that may interact with the risk to develop PD, but with 
considerable variability concerning degree and direction of the modification, as well 
as the quality and quantity of the available evidence. An interaction between genetic 
risk factors and environmental or other individual factors is suspected and has been 
shown in single studies. Overall, available evidence on risk-factors for PD explains 
only a minor proportion of cases and underlines the presumably heterogeneous 
etiology of this disorder.  
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Genetic factors 
Mitochondrial dysfunction, Į-synuclein accumulation and protein-mishandling in the 
ubiquitin-proteasome-system are pathways of a number of gene-mutations identified 
in PD.35,39 Some mutations cause classic Mendelian, familial parkinsonism with 
autosomal dominant or autosomal recessive heredity. Recent advances in genetic 
research have allowed genome-wide association studies and promoted the 
identification of a number of risk-loci. They are associated with modified risks to 
develop PD ranging from a 1,1 to 1,4-fold increased risk to 0,95 to 0,7-fold decreased 
risk to develop PD, which is accumulated when several risk-loci are present in the 
same individuals.20  
The first gene mutation identified in PD was in the Į-synuclein gene (SNCA, 
PARK1), a rare cause of autosomal dominant PD.61 A number of mutations in the 
gene lead to synthesis of abnormal Į-synuclein protein, which can impair 
mitochondrial function and accelerate formation of pathologic Į-synuclein 
aggregates.62,63 The clinical picture resembles classic PD in a proportion of cases, but 
for the rest, the clinical spectrum is broad with several atypical findings. Interestingly, 
cases with triplication of the gene present more severe phenotypes than duplication, 
indicating a relation between gene defect-dosage and severity.20,64
Mutations in the LRRK2-gene (leucin-rich repeat kinase 2, PARK8) are the most 
common known cause of autosomal dominant PD and several mutations associated 
with increased risk of PD have been identified. Clinical and histopathological changes 
resemble to a large extent sporadic PD with widespread typical Lewy-patholgy, but 
atypical cases and tau-pathology do also occur.20 Of special interest is the age-
dependent penetrance of the most common G2019S mutation in the LRRK2-gene, 
ranging from 28% at 59 years to 74% at 79 years, which leads to a pattern of sporadic 
occurrence.65
The most common mutations in autosomal recessive PD occur in the Parkin gene 
(PARK2) and may account for about 10% of young-onset PD cases. Lewy-bodies lack 
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usually, but were found in some cases.20,66 Mutations in PINK1 (PARK6) and DJ-1 
(PARK7) are less frequent, but clinics and pathology are in many aspects similar to 
Parkin-mutations.67
Age 
Increasing age is a known risk factor for both PD and other neurodegenerative 
diseases as e.g. Alzheimer’s disease. A systematic review of available incidence 
studies from 2003 documents an extremely rare occurrence of PD before the age 
of 40. The incidence is reported to 3ޤ10/100 000 at age 40ޤ49 and increases in some 
studies to over 100/100 000 for over 70 years old individuals. The peak-incidence is 
often found for the decade 70ޤ79 years, others report further increase for age 
above 80.68 The underlying mechanism is not resolved. Continuous increase of the 
incidence throughout all ages could indicate that neurodegeneration in PD simply is 
an exaggeration of normal aging, ultimately indicating that we all would develop PD 
if we lived long enough. Increased oxidative stress, mitochondrial dysfunction and 
abnormal protein deposition (including Į-synuclein) are joint features of both aging 
and PD, but the pattern of cell loss is different in PD and aging.69,70 Age-related 
changes may, however, increase the susceptibility for induction of Parkinson-specific 
neurodegeneration. The cause of this selective vulnerability is not clear, but 
dopaminergic neurons, especially their synapses, may be more prone to degeneration 
as production of dopamine increases oxidative stress.70
Gender 
Parkinson’s disease occurs in men about 1.5 times as frequent as in women, at least in 
western populations and with a considerable heterogeneity between studies.71-75 The 
male-preponderance seems to increase with age and is often absent in the group under 
60 years of age. In addition, there is no evidence for gender-related differences in the 
risk for PD in Asian populations, independent of age.72  
The onset of PD symptoms seems to be slightly delayed in women compared to 
men.76 Other reports on differences in the clinical appearance of PD in women vs. 
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men include more frequent initial presentation with tremor,76,77 worse instability 
scores in early PD,77,78 more problems related to sleep/fatigue and 
mood/cognition,77,79,80 more frequent or more severe dyskinesia,81-83 while REM sleep 
behaviour disorder (RBD) occurs more frequent in men.84 However, none of these 
findings is consistent in all reports, the overall severity of motor-symptoms is usually 
reported similar in men and women,76,78,79,81 and differences in the natural rate of 
progression have not been described. 
The most consistent gender difference in PD remains therefore the increased risk for 
PD in western men vs. women older than 60 years.72 Estrogens are thought to play a 
role here, as their neuroprotective effect on dopaminergic neurons has been 
demonstrated in animal models,85,86 and oestrogen can reduce oxidative stress and 
protect dopaminergic neurons against apoptosis.87 In accordance with that, Haaxma 
demonstrated better preserved dopaminergic activity in dopamine transporter imaging 
with single photon emission computed tomography (SPECT) in women vs. men with 
PD.76 But clinical studies show conflicting results. Women who underwent 
oophorectomy prior to menopause had an increased risk to develop PD,88,89 but no 
effect was found for early menopause or oestrogen-replacement therapy.88,90 A small 
clinical trial of oestrogen-use in women with PD showed improvement of motor 
symptoms, but follow-up was short.91 Inhibition of the dopamine-degrading enzyme 
Catechol-O-methyltransferase (COMT) by oestrogens may account for this 
symptomatic effect.92
Increased divergence of the risk curves after menopause-age and a similar risk for 
men and women at young age and in Asian populations indicate that oestrogens 
cannot be the only mediator of gender-related risk disparities. Alternative 
explanations include a gender-specific distribution of risk-genes, differential handling 
of Į-synuclein, chromosome X-mediated susceptibility and male lifestyle risk 
factors.93-96 However, also these mechanisms may finally be transmitted by oestrogen-
effects. 
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Lifestyle, environment and health-related factors 
A body of evidence suggests a slight reduction of the risk to develop PD for smoking 
or other use of tobacco or nicotine-containing fruits, as well as for caffeine 
consumption, also shown in our own study.96-98 A similar effect has been suspected 
for moderate alcohol consumption, but evidence is weaker.96,98 For humans exposed 
to pesticides in their environment, an increased risk to develop PD has been 
suggested,99-101 as also for farming, rural living and well water use, but causation has 
not been established.98 Gene-environment interaction may be of importance for these 
risk-factors and explain some of the heterogeneity in available evidence. 
Week evidence suggests a possible risk-reduction for PD by increased levels of uric 
acid, possibly due to its antioxidant effect, and by use of NSAIDs, particularly 
ibuprofen, possibly due to its anti-inflammatory properties.96,98  
1.3 Diagnosis and differential diagnosis 
1.3.1 Diagnosis 
The diagnosis of PD is based on anamnestic information about the symptoms and 
their development, clinical examination, response to dopaminergic treatment and 
observation over time. The cardinal symptoms include resting tremor, bradykinesia 
(slowness and poverty of movements with reduced amplitude), rigidity to passive 
joint movements and disturbances of gait and posture. Asymmetric distribution and 
symptom alleviation by levodopa are important supportive characteristics, and also 
the presence of olfactory dysfunction seems to be of confirmatory diagnostic 
value.102,103 Distinct cognitive impairment and severe autonomic disturbances may 
emerge subsequently, but are not typical for early PD.  
 Other causes of parkinsonism need to be excluded. Although some radiological 
features can, in addition to specific clinical symptoms and signs, support the diagnosis 
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of PD or other parkinsonian disorders, there is no reliable biomarker available for the 
diagnosis of PD. The gold standard for the definite diagnosis of PD therefore still 
remains the post mortem histopathological demonstration of neuronal loss in the 
substantia nigra with Lewy bodies in the remaining neurons.31
The difficulty to set a correct clinical diagnosis of PD has been demonstrated in 
clinico-pathological studies with an accuracy of less than 80% even for neurologists 
or physicians associated with a specialized centre for movement disorders.104,105
However, a later study showed improved clinical diagnostic accuracy to 90%, 
probably facilitated by application of clinical diagnostic criteria and increased 
awareness of the challenges in diagnosing PD.106
The most widely used clinical diagnostic criteria are those suggested by the United 
Kingdom Parkinson’s Disease Society Brain Bank (UKPDBB) in 1988 and those 
published by Gelb in 1999.30,31 Beyond their clinical significance, they are of special 
importance in the context of research, as a correct diagnosis of the included subjects 
is essential for adequate interpretation of the results. In both classifications, the 
diagnostic certainty increases when dopaminergic treatment improves symptoms and 
when observation over some years shows progression of the disease. The diagnosis of 
PD is therefore particularly challenging in patients with early and yet untreated 
parkinsonian symptoms. 
The diagnostic criteria of the UKPDBB and Gelb are presented in appendix I and II. 
1.3.2 Differential diagnosis 
Disorders that lead to symptoms as tremor, bradykinesia and gait problems are 
referred to as parkinsonism. Parkinson’s disease is the most frequent cause of 
parkinsonism, but there are several other distinct conditions that may lead to similar 
motor symptoms.  
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The most important and in early stages most challenging differential diagnoses are 
other progressive, neurodegenerative disorders which have their typical onset in the 
same age-groups as PD. 
Multiple system atrophy (MSA) is characterized by parkinsonism of varying severity 
with initial or early occurrence of autonomic failure (orthostatic hypotension and 
urogenital dysfunction) and affection of the corticospinal tract. The parkinsonian 
(MSA-P) subtype shows most similarities to PD and may initially even be asymmetric 
and respond to levodopa. In the cerebellar subtype (MSA-C), rapid progressing 
parkinsonism is associated with progressive cerebellar symptoms as gait- and limb 
ataxia and postural instability and with severe dysphagia. Neuropathologically, MSA 
is characterized by striatonigral and olivopontocerebellar degeneration with glial 
cytoplasmatic inclusions containing fibrillized Į-synuclein, and is therefore 
characterized as synucleinopathy in line with PD.107
Dementia with Lewy bodies (DLB) is defined by progressive cognitive decline early 
after or before parkinsonian symptoms emerge, with fluctuating cognition and 
recurrent visual hallucinations. REM sleep behaviour disorder and severe neuroleptic 
sensitivity occur frequently. Lewy body pathology is found in neurons in brainstem 
nuclei, especially the substantia nigra and nucleus ruber, and in various limbic and 
neocortical regions.108 Clinically and histopathologically, there may be a continuum 
from DLB via PD with dementia to PD without dementia.  
Progressive supranuclear palsy (PSP) is an akinetic-rigid parkinsonian syndrome with 
very early postural instability, vertical ocular gaze palsy (in early stages slow vertical 
saccades), early dysphagia and dysarthria, and frontal cognitive impairment.109
Median survival is only 5.6 years from diagnosis.110 In PSP, abnormal accumulations 
of tau-protein, so-called neurofibrillary tangles, are associated with neuronal loss in 
substantia nigra, subthalamic nucleus and globus pallidus, in addition to variable 
affection of other basal ganglia, diencephalon, cerebellar peduncles and the 
brainstem.111 Consequently, PSP is classified as tauopathy. 
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Another tauopathy is corticobasal degeneration, which typically shows pronounced 
asymmetric limb rigidity or akinesia with dystonia or myoclonus. Limb apraxia, 
cortical sensory deficit or the alien limb phenomen (non-recognition of the own limb) 
are additional diagnostic criteria. Dementia is in many cases a presenting or 
dominating feature of corticobasal degeneration.112 Neuronal loss with neuronal tau-
positive inclusions is found in the cortex, substantia nigra and globus pallidus with 
additional changes in other structures.113
Localized or disseminated cerebral vascular lesions are the cause of parkinsonian 
symptoms in vascular parkinsonism. The clinical signs include bradykinesia, rigidity 
and falls, but tremor is usually absent. The onset is later than in PD114 and often not, 
as widely suggested, acute, but insidious, with a relentless rather than stepwise further 
progression.115 Treatment with levodopa may lead to at least temporary improvement. 
However, symptoms are in most cases symmetric with predominant affection of the 
lower body, pyramidal signs (a red flag for the diagnosis of PD) are frequent, and 
pathological findings in structural neuroimaging are much more frequent than in 
PD.114,115  
A number of drugs can induce Parkinson-like symptoms. Most frequent are 
antipsychotics/neuroleptics, but also antiemetics, calcium-channel blockers, 
antidepressants and even some antiepileptics may cause extrapyramidal symptoms, 
primarily due to dopamine receptor type 1-antagonistic action. Drug induced 
parkinsonism is typically bilateral, symmetric, with more prominent bradykinesia and 
rigidity than in PD. However, 30-50% show asymmetric symptoms and tremor at rest, 
usually with postural tremor. Thus, clinical differentiation from PD can be difficult, 
especially as recovery after cessation of the actual drug can take weeks or months and 
is not always complete.116   
Further causes of secondary parkinsonism include infections (though seldom), toxins 
(e.g. MPTP, manganese and cyanide), structural lesions involving the basal ganglia 
(tumor, vascular malformation, ischemia, demyelination), hydrocephalus, multiple 
subcortical vascular lesions, head trauma and metabolic and endocrine disturbances. 
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Other examples are Wilson’s disease, the neurodegenerative Huntington disease ޤ
especially in young cases ޤ and the enzyme deficiency-related Neuroacanthocytosis 
and Gauchers disease. Tremor in PD may sometimes be difficult to distinguish from 
essential tremor or other tremor forms.  
1.3.3 Imaging 
Routine computed x-ray tomography (CT) and magnetic resonance imaging (MRI) 
are usually normal in PD and primarily used to exclude a range of secondary causes of 
parkinsonism. In a proportion of cases with MSA and PSP, routine MRI shows 
degenerative changes, which then can facilitate the diagnosis. Atrophy of the putamen 
is seen in MSA and PSP, but not in PD. Putaminal hyperintensity, a putaminal lateral 
hyperintense rim and a hyperintense cross-structure in the pons (“hot cross bun” sign) 
are typical for MSA-P, while midbrain atrophy with the “humming bird” sign 
indicates PSP. MRI with planimetry can visualize reduction of midbrain diameter and 
midbrain/pons area ratio in PSP.117 More advanced MRI techniques such as diffusion 
imaging, susceptibility weighted imaging and magnetic transfer imaging may increase 
the diagnostic value of MRI further, but it is unclear whether they can improve early 
diagnosis.117,118
SPECT (single photon emission computed tomography) and PET (positron emission 
tomography) use radioactive tracers to detect reduced presynaptic activity in 
dopamine-transporters or DOPA decarboxylase in the striatum. They are 
predominantly used to distinguish neurodegenerative parkinsonian disorders from 
non-degenerative conditions as essential tremor, but may have potential to 
differentiate between other neurodegenerative parkinsonisms as well.119,120,121
Interestingly, cardiac sympathetic denervation with decreased myocardial uptake of 
123I-mataoidobenzylguanidine in MIBG-SPECT is typical for PD already at early 
disease stages, but not for MSA, and may therefore be helpful to distinguish those 
conditions.122-124
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In the last decade, hyperechogenecity of the substantia nigra in transcranial 
sonography of the midtbrain in patients with PD has received increasing attention.125
It can confirm clinically suspected PD and identify individuals with increased risk to 
develop the disease, at least in research settings.124 Together with reduced olfaction 
and asymmetry of motor symptoms, high values for specificity and positive predictive 
value have been achieved.126  
1.4 Epidemiology 
Knowledge about the epidemiology of a disease provides information about its 
occurrence in the investigated population, differences compared to other geographic 
or ethnic populations, risk factors and trends over time. Thereby it contributes clues to 
understand factors related to the etiology of the condition and provides vital data for 
health care planning.  
The prevalence (number of individuals affected at a certain point of time in a defined 
population) of Parkinson’s disease in Norway was estimated to be 102/100 000 
inhabitants in the county of Rogaland in 1995, which was in line with several other 
European studies.127,128 As PD is a disease of later life, about 1% of the population 
65 years or older are thought to have PD.128,129 However, incidence rates (occurrence 
of new cases within a certain time period in a defined population) are considered a 
better measure for the frequency of a chronic disorder. Incidence numbers are better 
comparable between studies from different geographic, social, environmental or time 
areas, which are factors that affect the mortality of individuals with a disease and 
thereby the prevalence figures. 
Until 2009, there were no incidence numbers available for Norway. In other European 
countries the incidence of PD ranged from 5/100 000 to 26/100 000. Rather than real 
distinctions in the investigated European populations, it is assumed that variations in 
the applied methodology and age-distribution in the investigated countries account for 
these differences.68,128 Consistent throughout all studies are increasing incidence rates 
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with age. Some studies found the peak incidence between 70 and 80 years, while 
others report further increase after that. This has different consequences for 
etiological considerations (see “Etiology and risk factors”). However, diagnostic 
uncertainty increases in the oldest age-groups, and the smaller base population limits 
statistical power.128 Despite methodological differences, an increased risk for men vs. 
women with a male-to-female ratio of 1,3-1,9 has been shown for a clear majority of 
incidence studies in Europe and Northern America, but not Asian countries.72
Challenges in PD-epidemiology 
In a review on studies of the incidence of PD published until 2001, Twelves et al. 
found considerable methodological heterogeneity in the evaluated studies. This is 
problematic as the methodology has significant impact on the resulting incidence 
figures for PD:68,128
1. The method of case identification is important to achieve a collection of ideally 
all cases in the investigated area. Hospital data usually provide underestimates 
of the number of incident cases when patients also are diagnosed and treated in 
the primary health sector or by specialists outside the hospital. Door-to-door 
surveys are optimal in smaller base populations, but not feasible in large 
populations. It is of importance that the complete base-population is analysed.  
2. A correct diagnosis is crucial. Retrospective screening of records not designed 
to provide a basis for a correct diagnosis in the setting of a study is a source of 
diagnostic error. A wrong diagnosis of PD is more likely to be given from 
primary physicians and neurologists outside a study. Incidence studies are 
particularly sensitive to misdiagnosis as they aim to identify cases in the early 
phase of PD, when the differentiation from other parkinsonian disorders is 
difficult. Thus, the optimal approach for a correct diagnosis of PD is 
considered to be a prospective examination of all potential cases by study 
neurologists with follow-up for several years.68
3. The time-point of incidence needs clear definition. This may be the time when 
the first symptoms occur, which usually has to be determined retrospectively 
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with the corresponding uncertainties. An alternative is the first time a disease 
comes to medical attention. This provides a purely prospective approach and 
states the initial diagnosis later in the course of the disease with increased 
diagnostic certainty, but cases that die with the disease before getting to 
medical attention will be missed.  
4. The base population needs to be clearly defined and completely analysed with 
respect to incident cases. Moving to and from the study-area, as well as death, 
are challenging confounders that need to be handled according to defined 
criteria.  
Several of these factors favour western and southern Norway for the conduction of an 
incidence study on Parkinson’s disease. The health care system for neurological 
disorders is almost exclusively based on hospital-assigned specialists, and each 
hospital has defined geographic areas it is responsible to provide health care for. The 
guidelines of the Norwegian medical association assign the diagnosis of Parkinson’s 
disease and the initiation of antiparkinsonian treatment to specialists in neurology. 
Furthermore, the population is relatively stable especially for the population above 
40 years of age (Statistics Norway, www.ssb.no ). 
1.5 Clinical aspects 
1.5.1 Motor symptoms 
Parkinson’s disease is primarily defined by its motor symptoms, which also represent 
the basis for the clinical diagnosis. 
Tremor is an involuntary, rhythmical and oscillatory movement of a body part.130 It is 
one of the most obvious symptoms in PD, potentially stigmatizing and may have 
impact on daily activities when pronounced, but is not an independent predictor of 
reduced quality of life in patients with PD.131-133 PD-tremor is typically an 
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asymmetric, distal, 4-6Hz resting-tremor which disappears when the limb is moved, 
allowing the use of tools or to carry things.130 It is more frequently seen in the upper 
limbs compared to the lower, occurs occasionally in in the jaw muscles or tongue, but 
neck, trunk and hips are not affected.134 Some degree of tremor is reported in 70-80% 
of patients with PD during the course of the disease.135-137 It may be the initial 
symptom or occur later in the course, and it may disappear after some years.138 The 
severity of PD-tremor is not correlated to other motor symptoms, striatal dopamine 
depletion or histopathological nigrostriatal degeneration.139,140 It has been suggested 
that resting-tremor in PD is generated by a neuronal network outside the basal 
ganglia, in the cerebello-thalamico-cortical circuit.141
Bradykinesia describes slowness, reduced amplitude and poverty of movements. It is 
a major characteristic of PD, but also of other parkinsonian disorders. Impairment of 
automated movements is seen as reduced eye-blinking rate, reduced mimics leading to 
a “masked face”-expression, and reduced arm-swing when walking. Voluntary 
movements are affected with difficulties in fine motor tasks as buttoning and handling 
tools,142 all of that having consequences for daily life activities and social interaction.  
Bradykinesia is the clinical symptom that is strongest correlated to nigrostriatal 
dopaminergic deficit in Fluoro-dopa PET.143  
Rigidity describes increased muscular resistance to passive displacement of joints as 
the elbow, wrist, knee or ankle, but occurs also in proximal joints and the neck. It is 
usually not recognized by the patients themselves, and as such not directly relevant to 
them. But it is associated with increased muscle tone at rest, which patients may 
perceive as unpleasant and exhausting. Worse, it is associated with pain, and 
especially shoulder pain is not infrequently an early symptom of PD, but 
misdiagnosed as frozen shoulder or another musculo-sceletal disorder.142 Rigidity 
may appear smooth and continuous (“lead-pipe”-like) or staccato (“cogwheel”-like). 
Suspected pathophysiological mechanisms include increased activity of spinal cord 
motoneurons involved in the stretch reflex and increased primary motor cortex 
excitability, probably based on basal ganglia dysfunction.134
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A number of postural deformities are associated with rigidity. Elbows and knees are 
often flexed also in earlier cases, but in later stages flexed neck with antecollis, 
kyphosis, scoliosis and tilting of the trunk (Pisa syndrome) get more frequent.  
Gait problems include reduced speed, stride-length and elevation of the feet. One of 
the most disabling symptoms of PD is freezing of gait (FOG), a sudden, transient 
inability to move. It occurs when turning, starting to walk, walking through narrow 
spaces, when reaching a destination or – more “spontaneously” – in open spaces.142
FOG may occur already early in PD, but is then less frequent and of shorter duration. 
With progression of the disease, it gets more frequent and disabling, leads often to 
falls,144 and affects quality of life beyond its relation to mobility and gait.145 FOG is 
typical, but not specific for PD as it is also observed in PSP and MSA-P. The 
pathogenesis of this phenomenon is not clear, but basal ganglia, frontal lobe and 
motor pattern generators in the spinal cord may be involved.144,146
Postural instability and gait disturbances with resulting falls are closely related 
features predominantly present in later stages of PD. When falls occur early, the 
diagnostic focus should be led to other parkinsonian disorders as PSP or MSA. 
However, falls are overall frequent in PD and were reported in at mean 39% and 46% 
of patients, respectively, in two meta-analyses.147,148 Falling increases the risk for hip 
fractures,149 but more than actually falling, the fear of falling impairs the patients’ 
quality of life.150 One cause of falls are impaired postural reflexes, and many falls 
result from sudden changes in posture as turning of the trunk, or during transfer, e.g. 
from sitting to standing. Typically, PD patients fall forward, possibly due to the 
frequently stooped posture.144 Several mechanisms have been suggested as an 
underlying cause of the balance disturbances, including disturbed motor programing 
of postural corrections and central proprioceptive disturbances resulting in sway 
abnormalities, shift of the centre of gravity and overestimation of the limits of 
stability.144,151  
Speech problems in PD are characterized as hypokinetic dysarthria and comprise 
hypophonia (low voice volume), slurred articulation, a monotonous voice and 
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dysphonia (hoarse or harsh voice).152 Voice weakness may be present early, but 
problems increase with progression of the disease.153 Dysarthria has traditionally been 
attributed to muscle rigidity and hypokinesia due to dopamine deficiency, but 
improvement by dopaminergic stimulation is inconsistent,152 in line with the supposed 
involvement of cerebellar and cortical structures beyond the dopaminergic system.154  
1.5.2 Motor subtypes 
As Parkinson’s disease is heterogeneous with respect to prognosis, rate of progression 
and complications of the disease and its treatment, attempts have been made to define 
subgroups that share common characteristics. Classification into a tremor-dominant 
vs. non-tremor dominant subtype has repeatedly demonstrated significant differences 
between the subgroups. The allocation to one of these motor-subtypes depends on the 
relative severity of tremor vs. akinesia and rigidity,155 or tremor vs. postural 
symptoms and gait difficulties (PIGD),156 usually based on standardized scoring-
schemes as the Unified Parkinson’s Disease Rating Scale (UPDRS).157 It has been 
shown that the non-tremor dominant subtypes of PD are associated with higher 
mortality,158,159 more impaired quality of life and daily life functions,160,161 faster 
overall progression,162,163 increased cognitive decline,138,163,164 a higher number of 
non-motor symptoms,161 more autonomic dysfunction,165 drooling161 and sleep 
disturbances166 as compared to tremor-dominant patients. The pathophysiological 
background for these differences is not clear. Neuropathological studies have shown a 
higher cortical Lewy body load for the non-tremor subtype,167,168 which may explain 
increased dementia. One imaging study found a different pattern of striatal 
dopaminergic activity in FP-CIT-SPECT in tremor vs. non-tremor subtypes,169 and 
the same authors described later faster reduction of dopaminergic activity in akinetic-
rigid patients after 2,5 years follow-up, in line with the clinical progression.170
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1.5.3 Treatment-induced motor complications 
Dopaminergic treatment over time induces fluctuations and dyskinesia in a 
considerable number of patients, what has been observed already short after the 
introduction of levodopa in treatment of PD.171 Intermittent dosages of levodopa lead 
in the beginning to a continuous dopaminergic effect, but later in the course, 
parkinsonian symptoms re-emerge or increase before the next dose has become 
effective (“wearing-off”). Some patients develop fluctuations independent of 
medication intervals, with sudden, unpredictable shifts between “on” and “off” state. 
The unpredictable character of these “on-off” fluctuations can be the most difficult 
aspect of levodopa therapy for some patients.172 However, an association of motor-
fluctuations with impairment of quality of life parameters has only been documented 
in a minority of studies.133
Dyskinesia consist typically of involuntary, irregular, chorea-like or ballistic 
movements of the limbs, had and/or trunk, which occur as “peak dose” or “on period” 
dyskinesia, related to high plasma levels of levodopa. Less frequent are diphasic 
dyskinesia, emerging during the onset and offset of the levodopa-effect.173 Within the 
first years of PD, dyskinesia are very seldom, but the frequency increases with longer 
disease duration.174 Although dyskinesia can get distressing, disabling and even 
painful with increasing severity, their impact on quality of life is limited.133,175  
Treatment with the short acting levodopa induces fluctuations and dyskinesia more 
frequently than treatment with the longer acting dopamine agonists, probably related 
to the more pulsatile stimulation of post synaptic dopamine receptors.176-179 Changes 
in dopamine receptor affinity or in the N-methyl-D-aspartate (NMDA) receptors have 
been suggested as underlying causes of fluctuations.180 Mechanisms thought to cause 
dyskinesia include presynaptic dysfunction of dopamine storage and -release, and an 
abnormal pattern of neuronal activity in the basal ganglia, finally leading to abnormal 
recruitment of cortical motor areas.179,181
36
1.5.4 Non-motor symptoms 
James Parkinson mentioned already in his descriptions from 1817 constipation, 
urinary incontinence, drooling, sleep disturbances and daytime sleepiness as problems 
he had observed in the “shaking palsy”. He was not aware of cognitive impairment 
and stated “the senses and intellects being uninjured”.1 However, by the end of the 
nineteenth century, reports on impaired memory, dementia and depression in PD 
appeared. Lewy found in 1923 that 54 of 70 PD patients were affected by pronounced 
mental disturbances, mostly dementia.182 First from the 1990s, non-motor symptoms 
in PD gained considerable attention, and autonomic, sensory, neuropsychiatric and 
sleep-related symptoms are now widely accepted as important manifestations of 
PD.183,184 It is documented that non-motor symptoms have significant impact on 
patients’ quality of life,11,131,185 on their caregivers,186,187 and on health-economics,188
and that hallucinations are a dominating predictor of nursing home placement.189,190
Despite these facts, non-motor symptoms remain under-recognized by treating 
neurologists,191 in part related to the non-declaration of symptoms by the patients.192
One reason may be that patients do not associate non-motor symptoms with their 
Parkinson’s disease, and therefore do not mention them in consultations. The early 
emergence of several non-motor symptoms requires sound knowledge on the 
prevalence and severity of these features to improve care for patients newly diagnosed 
with PD. 
   
Neuropsychiatric symptoms 
Cognitive impairment and dementia 
Cognitive impairment is an overall frequent finding in PD, and in late stages the 
majority of patients will develop dementia.193,194 Cognitive problems initially 
comprise executive dysfunction, impaired attention, working memory, verbal memory 
and visuospatial abilities.195,196 These fronto-executive deficits lead to reduced 
organizational skills, impaired concentration, problems with retaining information 
while undertaking daily tasks and difficulties to focus attention, which interfere with 
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social and occupational functioning.197,198 With progression of the disease, cognitive 
function deteriorates further. In addition to the aggravated impairment of executive 
function, patients with PD-dementia show impaired short-term memory, 
hallucinations and fluctuating attention. Despite some problems with verbal memory, 
severe language problems, a typical feature of Alzheimer’s disease, are seldom.199
The deficits in mild cognitive impairment seem to reflect the involvement of 
brainstem nuclei in early PD,195 while the dominating finding in overt dementia is 
Lewy-body related degeneration in cortical and limbic structures.200 Increasing 
evidence suggests a significant role of Alzheimer’s disease like pathological changes 
and mechanisms in PD-dementia.201,202  
Depression 
Depression is one of the most frequent neuropsychiatric disturbances in PD, reported 
in 40-60% of patients, and may occur at any time throughout the course of the 
disease, also in the premotor phase.203,204 Depressive symptoms include low mood, 
decreased interest in usual activities, reduced pleasure in otherwise enjoyable 
undertakings (anhedonia), feelings of guilt and worthlessness, with suicidality in 
severe cases. These are often accomplished by more somatic problems like impaired 
concentration and sleep, fatigue or loss of energy, weight loss or changes in appetite, 
and by physical complaints as muscle tension and gastrointestinal symptoms.205 The 
latter features do overlap with symptoms also found in PD without depression, what 
may lead to non-recognition of depression as the underlying cause. Depressive 
symptoms interfere with most aspects of an individual’s life including family, 
occupation, daily and social activities, and are the most frequent reported contributor 
to reduced quality of life in PD.133 Depression may easily be interpreted as a reactive
phenomenon to the patients’ PD. However, more important seems to be the 
underlying neurodegenerative process, especially of the limbic system and basal 
ganglia.206 Dopaminergic, noradrenergic and serotonergic neuronal systems are 
affected, all involved in regulation of mood and reward systems in both PD and the 
general populations.204
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Fatigue 
The overall prevalence of fatigue in PD ranges in most studies from 30 to 65%, with 
presence already in early stages.207,208 It is one of the most disabling single symptoms 
that occur in PD, and has in 1/3 of patients in one study even outranged the PD-
specific motor symptoms.209 A major review on the issue quotes a patient: “I can live 
with the PD (not great, but livable), but the fatigue is unbearable.”210 Fatigue is a 
subjective perception and describes a sense of tiredness, lack of energy or 
inappropriate exhaustion with difficulties to initiate and sustain mental and physical 
tasks in the absence of motor or physical impairment.210 The character of this 
perception overlaps with other non-motor symptoms, and fatigue is often associated 
with depression or sleep problems. However, the principally independent character of 
fatigue is reflected in the frequent occurrence also in patients without depression, 
sleep problems or dementia.211,212 The pathophysiological mechanisms underlying 
fatigue in PD are poorly understood. A feedback loop in which pain, depression, 
fatigue, inactivity and deconditioning act synergistically to increase disability has 
been suggested by some authors,210,213 while others suppose that failure in the 
integration of limbic input and motor functions within the basal ganglia reduces 
motivation of self-initiated tasks.214,215  
Apathy 
Another mood-related symptom frequently present in PD is apathy, characterized by 
reduced interest and participation in the main activities of daily living, a lack of 
initiative, a trend toward early withdrawal from initiated activities, indifference and 
flattening of affect.216,217 Consequences include secondary increased functional 
decline, greater debility and familiar problems.216 The features of apathy overlap with 
those of depression and cognitive impairment, and although those conditions 
frequently occur in combination, some patients with PD show apathy in the absence 
of depression or dementia.218,219 Apathy may occur already as a presenting symptom 
at the time of diagnosis,220 and the prevalence for later stages ranges up to 70%.221
Thought underlying mechanisms include reduced limbic and ventral striatal 
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dopaminergic activity and involvement of the systems for reward, emotion and 
cognition.222,223,224
Psychosis 
Psychotic symptoms are unusual in the first years of PD, but present in 60% or more 
of patients with late stages.225-227 Most frequent are visual hallucinations, typically 
consisting of persons, less frequent of animals or objects. In less severe cases, patients 
have insight in the pathologic nature of the phenomenon, but this does not necessarily 
reduce the burden of experiencing hallucinations. Minor psychotic phenomena 
include visual illusions (misinterpretation of a real stimulus) and a sense of presence 
or passage, although nobody is there or passes by.228,229 The risk for psychotic 
symptoms increases with older age, longer duration and greater severity of PD.228
Also dopaminergic medication seems associated with psychotic symptoms, but 
findings are not consistent.230 Complex interactions between disease and treatment-
related effects are more likely to account for the development of psychosis, including 
impaired visual input and cognitive impairment leading to disinhibited release of 
stored visual memories.228,230
Anxiety 
Anxiety disorders are reported in 30-40% of patients with PD, and most common are 
panic attacks, social phobia and generalized anxiety. Patients perceive excessive and 
often irrational anxiety or worry, nervousness, irritability, feelings of impending 
disaster, palpitations, hyperventilation and insomnia.134,216,231 Anxiety is frequently, 
but not always related to fluctuations, especially the “off” state. Patients with anxiety 
have often coexisting depression and predominantly a non-tremor dominant motor 
subtype.231,232 Anxiety may occur at any stage of PD, including the premotor phase, 
what probably represents the involvement of brainstem structures as raphe nuclei and 
locus coeruleus as well as the beginning dopaminergic deficit.134,230,233
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Autonomic and gastrointestinal symptoms 
The autonomic nervous system controls a large spectrum of visceral body functions, 
ultimately in order to maintain homeostasis and – thereby – ensure survival. 
Cardiovascular, genito-urinary, respiratory and elements of visual function as well as 
temperature are, largely involuntary, regulated by the parasympathetic and 
sympathetic nervous system. Gastrointestinal organs are in addition, and to a large 
extent, controlled by the enteric nervous system. The peripheral structures include 
neurons with ganglia localized paravertebral or closer to the endorgans, while the 
enteric nervous system is placed in the layers of the intestine walls. The immediate 
target structures are smooth muscles of organs as the intestine and urinary bladder to 
regulate peristaltic and release, blood vessels for control of blood pressure and 
perfusion, cardiac muscles to adjust frequency and contraction strength to the 
requirements, as well as glands for secretion. It is necessary to adapt these functions 
to the context of the current and superior circumstances of the individual. The core 
central structure for this is the hypothalamus, which integrates autonomic, endocrine, 
limbic and somatic information in order to achieve the optimal reactions, both 
autonomic and somatic. Other central autonomic structures as the reticular substance 
and autonomic nuclei in the brainstem are to some degree independent, but under 
superior control of the hypothalamus.234,235 Affection of brainstem, enteric plexus and 
other peripheral autonomic structures by Lewy-body-related neurodegeneration is 
thought to represent the histopatholgical correlate of autonomic disturbances observed 
in PD patients also before the onset of motor symptoms,201,236-238 as reflected in the 
Braak-hypothesis19 and more recent suggestions of a peripheral induction of the 
neuropathological cascade.55-57 The substantial presence of autonomic disturbances in 
the later stages of PD is well established.194,239,240 However, by 2010, the frequency 
and severity of such symptoms in the earliest stages of PD was very insufficiently 
documented and predominantly derived from hospital-based, small cohorts not 
reflecting the large clinical variety of PD and mostly focused on few 
symptoms.53,241,242 The considerable impact on quality of life as well as diagnostic and 
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therapeutic considerations require improved knowledge on autonomic symptoms in 
early stage PD. 
Orthostatic hypotension 
Maintaining blood circulation to brain and heart is absolutely prioritized in 
cardiovascular regulation and ensured by a system including baroreceptors, direct 
cardiac and vascular innervation and hormonal systems. A change of posture from 
laying to standing requires contraction of peripheral blood vessels and increased 
cardiac output to counteract gravity-induced hypotension in upper body regions. 
Failure of this system can lead to suboptimal cerebral perfusion clinically 
recognizable as dizziness or lightheadedness, weakness, nausea, pain or unclear 
vision and can in severe cases cause loss of consciousness.235 Symptoms of orthostatic 
hypotension become more frequent with increasing age and are present in 5-30% of 
the normal population above 65 years.243 A review from 2011 found clearly higher 
numbers in PD, with a pooled prevalence of 30%, ranging from10 to 65%.244 In only 
two of the 25 studies included, the disease-duration was <5 years, and these reported 
14% and 18% prevalence, respectively. The basic pathophysiological mechanisms of 
orthostatic hypotension in PD include peripheral sympathetic denervation of 
resistance vessels and the heart,245 as demonstrated for example by pathologic cardiac 
radionuclide scans.246,247 In addition, insufficient intake of liquids and side effects of 
Parkinson-specific medication may be of importance.235
Sweating disturbances 
Hyper- or hypohidrosis is reported to occur in overall 30-50% of patients with 
PD.248,249 Hyperhidrosis is unpleasant, socially embarrassing and can affect quality of 
life.250 Typical locations are head, face, neck and chest, and it is frequently related to 
“off” periods in patients with “wearing-off”, or to dyskinesia.250 Compensatory 
hyperhidrosis secondary to hypohidrosis of the palm has been suggested as an 
underlying mechanism.251 But also heat intolerance and hypohidrosis are reported in 
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PD, what may indicate a more complex affection of the thermoregulatory system with 
both central and peripheral mechanisms.248
Genito-urinary dysfunction 
Storage of urine in the bladder and its controlled release are functions of the lower 
urinary tract, and symptomatic disturbances have been reported in about 30-70% of 
patients with PD. Most frequent are storage-related symptoms like nocturia, urinary 
frequency, urgency and incontinence, which in this order represent increasing 
dysfunction.252,253 Underlying these symptoms is an overactive bladder due to 
impaired control by a complex circuit including the pontine micturition centre, basal 
ganglia, cerebellum, hypothalamus and frontal cortex.252 Parasympathetic denervation 
with impaired detrusor activity is thought to account for the less frequent voiding 
problems, which include hesitancy (delayed start of urination), weak stream and 
incomplete emptying.254,255 The net effect of the basal ganglia on micturition is 
thought to be inhibitory,252 and some authors suggest that storage problems in PD are 
mainly the result of dopamine deficiency-related hyperactivation of the micturation 
reflex.255 However, the effect of dopaminergic treatment on urinary dysfunction is 
reported very controversial, indicating a more complex and variable interaction of 
central and peripheral mechanisms.252,256
PD patients are more dissatisfied with their sexual function and relationship than 
controls.257 Sexual problems include decreased or increased libido, erectile 
dysfunction and decreased frequency of orgasm.258 While hypersexuality is 
considered a side-effect of dopaminergic medication, hyposexual problems are 
thought to relate to the dopaminergic deficiency, affection of hypothalamus and 
sensory systems as well as sympathetic dysfunction.255,258  
Constipation 
Constipation is the most frequent gastrointestinal symptom typically reported in 
50ޤ70% of PD patients.259-261 Reduced bowel movement frequency, increased stool 
consistency and incomplete emptying may cause discomfort or pain and interfere with 
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appetite and daily activities, but severe constipation is not very frequent.262 Slow 
colonic transit, decreased phasic rectal contraction, weak abdominal strain and 
paradoxical sphincter contraction on defecation have been found in PD.263 It is likely 
that these problems reflect impaired autonomic control by the vagal nerve, enteric 
nervous system and sacral parasympathetic structures, which are affected by Į-
synuclein-related pathology.264,265 Constipation occurs often before the typical motor 
symptoms, and a reduced frequency of bowel movements is associated with an up to 
4-times increased risk to develop PD later.54 These findings have given raise to the 
hypothesis that the pathophysiological process of PD may actually start in the 
gastrointestinal system.56,57  
Dysphagia 
Subjective difficulties related to swallowing of food or liquids are reported by about 
30ޤ40% of PD patients, according to a recent meta-analysis.266 Problems include 
reduced speed of oral preparation, slow oral transit, misdirected swallows with 
increased risk of aspiration and residual food in mouth or pharynx.267 When 
objectively examined, over 80% of PD patients have abnormalities in the oral, 
pharyngeal or esophageal phase of swallowing,266 most common being impaired 
mastication and oral preparatory lingual movements.268 Dysphagia is usually not 
present before the onset of motor symptoms and more typical for later stages of 
PD.260,269 The impact of dysphagia on the patients’ and their caregivers’ life is beyond 
chewing and swallowing, but affects also practical and social activities surrounding 
mealtimes.270 Swallowing is a complex and stereotyped sequential process with 
interaction of voluntary and autonomic aspects, coordinated by a central pattern 
generator in the medulla. It is thought that affection of the pedunculopontine nucleus 
in PD causes impaired modulation of this medullary pattern generator, thereby leading 
to reduced control of swallowing.271,272  
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Drooling  
Problems related to increased and decreased amounts of saliva both occur in PD, and 
dribbling can be present in more than half of the patients.273 Severity and frequency of 
drooling increase with progression of the disease, and overt drooling is best known 
from patients in advanced stages.273,274 While hyposalivation may lead to subjective 
discomfort and teeth-problems, increased saliva in mouth or drooling are 
embarrassing especially in social settings.275 Sialometric studies have shown that 
saliva production is lower in PD patients, including early stages, compared to 
controls. Dopaminergic treatment stimulates saliva-production, but also treated 
patients produce still less saliva than controls.276-278 Central mechanisms and Lewy-
body pathology in the submandibular glands may explain this impairment of saliva-
production.278,279 Accumulation in, and loss of saliva from mouth are probably related 
to altered facial, oral and pharyngeal function, leading to reduced capacity to keep 
saliva in mouth, transport it backwards in the mouth and swallow it frequently 
enough.274,280 Saliva-accumulation in the mouth or drooling only during night time 
have been reported in 43% of patients in one study, and the authors suggest that these 
symptoms may precede actual daytime drooling.281
Sensory symptoms 
Hyposmia 
Olfactory dysfunction is a well-established non-motor feature of PD which has been 
found in up to 90% of patients, depending on the tests applied.282,283 This number is 
about 3ޤ4 times that of healthy older adults284 and exceeds even the 70ޤ80% 
prevalence of the cardinal motor feature tremor.136,137 The ability to detect, identify 
and discriminate odours is impaired unrelated to specific odorants, but total anosmia 
is rare.52,283 Reduced olfaction precedes the clinical motor symptoms of PD by 
probably 2ޤ7 years,28 and otherwise unexplained hyposmia is a risk factor for later 
development of motor PD.285-287 Although there is some evidence for a certain 
progression of the olfactory deficits during the early phase of PD,52,288 it is generally 
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accepted as a very early established and rather stable deficit.283,289 Based on its robust 
and high prevalence, hyposmia has been suggested and used as a supportive 
diagnostic feature for PD,102,103 also well discriminating PD from other movement 
disorders like PSP, MSA, corticobasal degeneration and essential tremor.290-292 The 
basis for impaired olfaction in PD is probably located in the olfactory bulb and 
olfactory cortex, where Lewy bodies and related pathology have been found.19,293,294
Together with the enteric system, the olfactory system is hypothesized to be the locus 
where the initial PD-specific pathophysiological changes take place before further 
centripetal propagation according to the Braak hypothesis.19,56,57
Pain 
Pain is frequent in the normal population, but even more frequent in patients with 
PD.295,296 It is one of the 5 most frequent complaints already in early stages and the 
prevalence ranges from 40 to 85% according to a recent review, likely also depending 
on the assessment tools.297,298 Most frequent is musculoskeletal pain, followed by 
dystonic and radicular-neuropathic pain, while central PD-related pain is relatively 
rare.298,299 The characteristic of pain is often difficult to describe, and in addition to 
distinct pain, patients report abnormal sensations like cramping, numbness and 
tingling, which with increasing intensity become painful. Muscular stiffness, reduced 
mobility and pathologic posture can explain a large proportion of pain and sensory 
complaints. In addition are both peripheral and central parts of the nociceptive system 
affected in PD, with pathological findings in cutaneous nerve endings, the spinal cord 
and various brain stem nuclei involved in descending regulation of pain.19,300,301 Also 
the basal ganglia are probably involved in pain processing, and hyperalgesia in 
response to pain stimuli has been reported in several studies.302 An association of pain 
with female gender, fluctuations and depression has been shown, but longer disease 
duration seems not to increase the occurrence of pain. However, findings on risk 
factors are generally inconsistent.303 Problematically, pain is not specifically treated in 
about half of PD patients.298  
46
Sleep-related problems 
Sleep-related disturbances are amongst the most important problems for patients with 
PD,304 interfere with quality of life and often affect also the spouses consider-
ably.305,306 Most frequent is insomnia, with difficulties to maintain sleep, fall asleep or 
too early awakening in the morning.307,308 Night time motor problems like difficulties 
turning in bed, tremor and early morning dystonia as well as a number of non-motor 
problems like nocturia, pain and depression interfere with sleep,309 in addition to 
dopamingergic medication.310 Restless legs syndrome occurs predominantly at the 
beginning of sleep with disagreeable restless feelings in the lower limbs which often 
only relieve by moving the legs,311 but the condition overlaps with leg motor 
restlessness without diurnal fluctuations.312 During REM-sleep, voluntary muscles are 
usually atonic. In REM-sleep behaviour disorder (RBD), this atonia is absent and 
patients act out their dreams, with increased risk for injuries of both the patient and 
bed partner.311 Lower brainstem pathology is thought to account for RBD, what is, 
reminding Braaks hypothesis,19 in line with its frequent emergence before PD-motor 
symptoms and the fact that apparently idiopathic RBD is associated with an increased 
risk for PD.313  
Common in PD is also excessive daytime sleepiness, an increased tendency to fall 
asleep during the day. PD-pathology, disturbed night time sleep and sedative drugs 
are contributing mechanisms, in addition to dopaminergic drugs, which are also 
suspected to induce sleep attacks as a class effect.311,314
1.5.5 Treatment-related non-motor complications 
A number of non-motor symptoms potentially deteriorate at least to some degree due 
to dopaminergic treatment, but there are considerable interindividual differences and 
evidence is conflicting. Generally, it is thought that constipation, orthostatic 
hypotension, daytime sleepiness and especially psychotic symptoms may worsen due 
to treatment with either levodopa or dopamine agonists. However, with progression of 
the disease and increasing duration of levodopa therapy, non-motor fluctuations have 
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been observed in autonomic, cognitive/psychiatric and sensory symptoms, resulting in 
significant disability mostly associated with the “off” state.315  
Impulse control disorders 
Distinct complications of dopaminergic therapy rather than PD-specific pathology are 
impulse control disorders (ICD), defined as the failure to resist an impulse or 
temptation to perform an act that is harmful to the individual or to others. They have 
been described in 6-17% of patients and include pathological gambling, hypersexual 
behaviour, compulsive shopping, compulsive eating and punding (intense fascination 
with repetitive handling, examining, sorting and arranging of objects).316 Despite a 
clear association with use of dopamine agonists, more than levodopa, there is 
evidence that male gender (mostly for hypersexual behaviour and gambling), younger 
age and certain personality traits are predisposing factors for ICDs.317 Dopaminergic 
pathways are involved in the brain’s reward system and development of addiction, 
and are thought to play a key role in the generation of ICDs. Reduction or cessation of 
dopaminergic treatment, or switching to another dopamine-agonist, will usually 
improve ICDs.316  
1.6 Quality of life 
Quality of life is by the WHO defined as the “individuals’ perception of their position 
in life in the context of the culture and value system in which they live and in relation 
to their goals, expectations, standards and concerns”. This includes the “individuals’ 
health, psychological state, level of independence, social relationships, personal 
beliefs and their relationship to salient features of their environment”.318 Essentially, 
quality of life is a subjective perception of the own well-being. It is multi-dimensional 
and includes physical, mental, social and spiritual aspects.  
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Quality of life in medicine 
A role of medicine in quality of life (QoL), and vice-versa, has already in 1966 been 
highlighted in an editorial by Elkington, exemplified on patients undergoing renal 
transplant,319 and the development of generic QoL measures began in the early 1970s. 
Subsequently, QoL assessments were highlighted as a factor in resource allocation in 
health care,320 while others demanded to use quality of life measures in the evaluation 
of the care given, rather than the justification for giving care.321,322 Independent of 
this, QoL became an increasing focus in clinical research, as it supplied a highly 
relevant aspect to the outcome-measures of clinical trials and for understanding 
different aspects of medical conditions. The term health-related quality of life 
(HRQoL) was introduced to include both personal health status and social well-being 
when assessing health.323 Usually, assessments cover a range of different aspects of 
quality of life, including physical, mental, social and health-related aspects. 
Quality of life in PD 
A chronic, progressive disorder like Parkinson’s disease, which is characterized by a 
wide range of motor and non-motor symptoms and leads to severe disability over 
time, will naturally interfere with quality of life. Consequently, quality of life has in 
the past decades been recognized as a relevant aspect of health, disease, treatment and 
research also in PD.324 A number of generic (general) and disease-specific scales are 
now available to assess health-related quality of life.325 Compared to the normal 
population, all aspects of quality of life are reduced in PD patients, and more so with 
increasing duration and more advanced disease.326,327 It has also been demonstrated 
that both motor and non-motor symptoms have impact on HRQoL.131,328 There is, 
however, controversy as to whether non-motor symptoms are more relevant than 
motor symptoms in tis respect.329,330 A review from 2011 concluded that the most 
frequently reported determinant of reduced HRQoL in PD was the presence of 
depressive symptoms, followed by severity and disability of the disease.133
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There are several challenges concerning the impact of motor and non-motor 
symptoms on HRQoL in PD: As patients frequently not report non-motor symptoms 
to their health-care personnel, these symptoms often remain not appropriately 
treated.192 The resulting higher severity compared to the better treated motor 
symptoms has been suspected as the cause of a relatively stronger impact of non-
motor symptoms on HRQoL measures.330 Progression of PD goes along with changes 
in prevalence, severity and relative dominance of both motor and non-motor 
symptoms.138,239,331 It can, consequently, be expected that the impact of different 
symptoms on HRQoL will vary during the course of the disease, but few reports have 
focused on a specific stage or phase of PD.332,333 Until 2013, only one has investigated 
the impact of a variety of symptoms in the very early phase of PD.333
The multitude of motor and non-motor symptoms is another challenge for 
investigations, and most studies have focused on the impact of single symptoms or 
symptom-groups on HRQoL in PD, neglecting the impact of other symptoms.133
There is also a variety of assessment tools for all symptoms with unequal detailedness 
and metric characteristics. All these factors hamper the judgment and comparability of 
studies that have assessed the importance of motor versus non-motor symptoms 
in PD. 
Solid knowledge on the relative impact which the very different symptoms of PD 
have on quality of life will help to understand the patient’s needs, and to focus efforts 
in clinical treatment as well as research. 
1.7 Treatment 
Treatment of PD, as of other disorders, includes the principal goals disease 
modification and symptom modification. The neurodegenerative process underlying 
idiopathic PD has up to date not been possible to prevent, reverse, arrest or even to 
retard substantially. Treatment in PD relies therefore today heavily on 
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pharmacological symptom control, while some non-pharmacological strategies may 
provide additional benefit.  
1.7.1 Treatment for motor symptoms 
MAO-B inhibitors 
Monoamine oxidase type B (MAO-B) is an enzyme of the outer mitochondria 
membrane primarily found in glia cells around dopaminergic synapses in the brain. It 
metabolizes neurotransmitters including dopamine, and inhibition of MAO-B 
increases striatal extracellular dopamine levels.334 This is reflected in a slight 
symptom-improving effect documented for the two currently available MAO-B 
inhibitors Selegiline and Rasagiline.335,336 They are therefore recommended as an 
option for symptomatic treatment in early PD or as add-on to reduce fluctuations in 
patients on dopaminergic medication.337 Nausea, headache and vertigo are usual side 
effects. Selegiline may induce insomnia due to its metabolite metamphetamine, which 
is not produced in the metabolization of Rasagiline.  
There is some evidence that MAO-B inhibitors may delay progression of PD to a 
minor extent, presumably due to a neuroprotective effect.338-340 As the findings are 
discussed, the drugs are not clearly recommended for neuroprotective treatment 
in PD.341,342
Levodopa 
With its introduction in the 1960s, levodopa has revolutionized the treatment and 
prognosis of PD. In contrast to dopamine, it easily crosses the blood-brain barrier and 
is then metabolized to dopamine by the enzyme DOPA decarboxylase, thus 
substituting the reduced amount of endogenous dopamine, i.a. in the basal ganglia. As 
DOPA decarboxylase is also present outside the brain, levodopa is given together 
with the peripheral decarboxylase inhibitors carbidopa or benserazide. They increase 
central bioavailability and reduce dopamine-induced peripheral side-effects like 
nausea.343 Levodopa is still regarded as the most effective drug to treat the motor 
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symptoms of PD,344 best reducing hypokinesia and rigidity, and in a proportion of 
patients also tremor. However, axial symptoms and gait problems do usually respond 
less well to levodopa, and long term use leads in the majority of patients to 
fluctuations and dyskinesia.344,345 Other side effects are, however, less frequent 
compared to dopamine agonists. To reduce the complications of levodopa it is usually 
not given as initial treatment in younger patients with longer life expectancy. Also a 
neurotoxic effect of levodopa has been suggested, but evidence for that has not been 
established.346  
COMT-inhibitors 
Levodopa is in the periphery and to a minor degree in the central nervous system also 
metabolized by the enzyme catechol-O-methyl transferase (COMT), mainly localized 
in the liver. Inhibition of COMT extends the half-life of levodopa and provides a 
more continuous availability of levodopa to the brain.347 Entacapone is the by far most 
frequent used COMT-inhibitor today, as Tolcapone has in rare cases led to fatal liver 
toxicity. COMT-inhibitors are given as adjuncts to levodopa, and have shown to 
increase the levodopa effect and reduce “off” time and “off” severity in fluctuating 
patients.348,349 Pronounced diarrhea limits unfortunately the use in some patients. 
Dopamine agonists 
Bromocriptine was the first oral dopamine agonists, introduced in the 1970s. It was an 
ergot-derivate, in line with the other first-generation agonists, in contrast to the non-
ergot derivatives introduced later. Oral dopamine agonists have a differential affinity 
especially to D1 and D2 dopamine receptors, but their main advantage compared to 
levodopa is the longer half-life.350 This is thought to be the primary cause of why 
dopamine agonists have less potential to induce fluctuations and dyskinesia, a widely 
documented benefit.177,351,352 However, the dopaminergic effect is weaker compared 
to levodopa, while side effects as nausea, daytime somnolence and peripheral oedema 
are more prominent. They are consequently usually recommended as primary 
treatment for monotherapy in younger patients, but may also be effective as 
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supplement to levodopa to reduce fluctuations.337,353 As dopamine agonists on ergot 
basis have shown a considerable risk to induce cardiac valve fibrosis, their use has 
become restricted and very limited.354 Ropinirole, Pramipexole, Rotigotine and 
Piribedil are non-ergot agonists used today, Rotigotine as a transdermal patch. In 
recent years, the induction of impulse-control disorders has been recognized as a 
problematic side effect of all agonists, requiring  specific attention and follow-up by 
the treating physician.355
Amantadine and Anticholinergics 
The use of Amantadine and anticholinergic drugs (effective for tremor) is very 
frequent associated with side effects leading to discontinuation of treatment short 
after the initiation, and these drugs are no longer recommended in the Norwegian 
guidelines for treatment of PD.356
More advanced pharmacological treatment 
Based on the disadvantages of pulsatile dopaminergic stimulation, methods for 
continuous application of dopaminergic drugs have been developed. They include 
today the subcutaneous infusion of the by itself very short acting dopamine agonist 
apomorphine and the intraduodenal application of a levodopa suspension via 
percutaneous endoscopic gastrostomy (PEG), both using an external pump. These 
treatment forms are primarily used in patients with advanced PD and more or less 
severe fluctuations.357
Surgery 
For patients with advanced PD complicated by disability from motor fluctuations, 
dyskinesia or tremor despite optimal drug therapy, deep brain stimulation (DBS) of 
the nucleus subthalamicus (STN), globus pallidus internus (GPi) or ventral 
intermediate nucleus of the thalamus (Vim) has become a to some extent established 
treatment option. Fluctuations and dyskinesia are diminished by both STN- and GPi-
DBS, but dopaminergic medication can be reduced more after STN-DBS, while 
53
cognitive and psychiatric side effects are less prominent in GPi-DBS. Proper selection 
of patients with a reliable diagnosis of PD, distinct symptom improvement by 
levodopa, no or only mild cognitive impairment and no or well controlled psychiatric 
problems, is necessary to ensure satisfactory benefit from the surgical intervention.10  
Medication-resistant tremor is usually markedly improved by DBS of the Vim.358
Non-pharmacological treatment 
Physical exercise is generally regarded to be of critical importance for PD patients.359
Physical therapy in general is also in recent evidence-based recommendations rated as 
likely effective as symptomatic adjunct to levodopa and includes general exercise as 
well as movement strategy training with cuing and focussed attention. Speech therapy 
may improve dysarthria and dysphonia in some patients, but the evidence is 
insufficient for recommendations. The currently available studies do not enable to 
conclude on the use of occupational therapy and acupuncture in PD.337,353
1.7.2 Treatment for non-motor symptoms 
Neuropsychiatric symptoms 
Cognitive impairment in PD is associated with cortical cholinergic deficiency. The 
cholinesterase inhibitor Rivastigmin has shown well documented improvement of 
memory, attention and concentration.360 The evidence for other cholinesterase 
inhibitors and the antiglutaminergic drug Memantine is weaker.337,361 Adverse effects 
include nausea, tremor and urinary dysfunction. 
Depression may be associated with suboptimal symptom control and fluctuations in 
PD, thus optimizing the dopaminergic therapy should be attempted. Pramipexole has 
shown an antidepressive effect independent of its impact on motor symptoms.362 Use 
of the antidepressive selective serotonin reuptake inhibitors (SSRIs) is often 
necessary, but their effectiveness in PD is not optimally documented.363
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As anxiety frequently is linked to depression, treatment with SSRIs can be effective. 
Optimized dopaminergic therapy is recommended, especially when anxiety occurs as 
part of the “off” state in fluctuating patients.361 There is some evidence supporting 
cognitive behavioural therapy at least in the acute management of anxiety and 
depression.364 Patients may have worries related to their future, the disease itself or 
their social situation, and corresponding measures will usually be at least of some 
help.  
There is currently no established treatment for apathy in PD.  Dopaminergic therapy 
should be optimized and comorbid depression treated first. In patients with cognitive 
impairment, also apathy may improve on treatment with cholinesterase 
inhibitors.230,361
In patients with fatigue, contributing factors like lack of sleep, depression, anxiety 
and orthostatic hypotension should be excluded or managed first, and patients may 
benefit from physical exercise. Methylphenidate, a dopamine transporter blocker, and 
Modafinil, primarily used to treat narkolepsy, improved fatigue in single studies.365,366
When psychosis and hallucinations occur, anticholinergic drugs, MAOB-inhibitors 
and Amantadine need to be withdrawn, dopamine agonists reduced or withdrawn. 
When improvement lacks, also levodopa should be lowered as far as possible.361
Consistent evidence exists for effectiveness of the atypic antipsychotic Clozapine, but 
the risk of serious side-effects requires caution and monitoring. In clinical praxis, 
Quetiapin is frequently used, although the evidence is conflicting.365
Autonomic and gastrointestinal symptoms 
For orthostatic hypotension it is recommended to try non-pharmacological measures 
first, such as sleeping in a head-up position to reduce night time hypertension, 
fragmentation of meals, avoidance of carbohydrate-rich meals, increased intake of 
water and salt, elastic stockings and increased physical activity.235,365 Pharmacological 
treatment options include Fludrocortison to increase plasma volume, or the 
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sympathomimetic acting Midrodrine and Dihydroxyphenylserine, which have shown 
some efficacy in orthostatic hypotension, although not consistently.367,368
Literature concerning treatment of sweating disturbances in PD is extremely limited. 
As drenching sweats may occur as an “off” symptom, optimized dopaminergic 
therapy may lead to alleviation in those cases,369 what is supported by a case report on 
improved off-related sweating after STN-DBS.370
Patients with significant urinary dysfunction should usually be examined by an 
urologist. Night-time polyuria can improve when fluid intake in the evening is 
reduced, but treatment with intranasal Desmopressin may be needed to reduce 
nocturnal urine production.371 Urgency and incontinence related to detrusor 
hyperreflexia have shown improvement on anticholinergics, but cognitive function 
may worsen.337,361 Bladder capacity and voiding volumes have shown improvement 
after DBS, but do not by themselves represent an indication for operative treatment.372
For erectile dysfunction, improved dopaminergic treatment or subcutaneous injection 
of apomorphine have been suggested by some authors.258,373 Phosphodiesterase-5 
inhibitors have shown effect in one small, randomized trial.374
In cases of mild constipation the focus should be on increased intake of fluid and 
fibre, psyllium preparations and adequate physical activity, while anticholinergic 
drugs are to be avoided. For more severe cases, regular intake of stool softeners and 
intermittent use of laxatives is needed.267 Macrogol is formally tested in PD patients 
and improved stool frequency and consistency.375 Sufficient dopaminergic treatment 
should be ensured especially when defecation problems are “off” state-related.361  
Patients with dysphagia will often profit from practical adaptions like taking more 
time to eat, a correct sitting position, smaller bites and careful fluid supplementation. 
Adaptations of the food itself may be needed, and in more severe cases thickeners for 
fluids are required. Levodopa and apomorphine have led to improvement at least in 
patients with early PD, indicating that optimized dopaminergic treatment and timing 
of meals to the “on” period may be reasonable efforts.337,376
56
As drooling is linked to oral, facial and pharyngeal function, improvement of these 
motor aspects by dopaminergic therapy sometimes reduces drooling. Xerostomia is a 
side effect of antidepressants and anticholinergics, which may be appreciated in 
drooling patients, although other side effects can limit the use.377 Botulinum toxin 
injected in the salivatory glands is considered effective in a recent review.365 As saliva 
production in PD patients generally is lowered despite excess from the mouth, utterly 
reduction of saliva increases the risk for problems with eating and dental health.  
Pain and sleep-related problems 
The management of pain in PD depends on the type of pain, requires often a 
multidisciplinary approach, and underlying causes should be eliminated.361
Modification of dopaminergic treatment can reduce “off”-related pain and pain 
secondary to impaired mobility and posture, and is the first choice for central PD-
related pain. Physiotherapy and general exercise are indicated in musculoskeletal 
pain. Direct analgesic treatment may be necessary in all pain types, including 
NSAIDs, tricyclic antidepressants, SSRIs, antiepileptic agents and opioid 
analgesics.366
Insomnia requires an initial analysis of sleep-related activities at both day and night-
time. Restoring proper routines for timing of meals and bedtime can reduce problems 
falling asleep. For patients with difficulties to maintain sleep, some authors 
recommend increased dopaminergic treatment dosages short before bedtime to reduce 
off-related disturbances during the night.378  However, this strategy may at least in 
early PD lead to poorer sleep quality and less REM sleep.310 Hypnotics and other 
sedating medication are often required, but when their half-life is long, they may 
cause or increase daytime somnolence. The latter can also be a side effect of 
dopaminergic treatment, especially dopamine agonists.378 For REM sleep behaviour 
disorder, Clonazepam is currently the standard treatment, but careful dose titration 
due to possible resulting daytime somnolence is also here required.311
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2. Aims of the study 
The overall aim of this study was to present improved evidence of the incidence and 
clinical characteristics of early PD with focus on non-motor features. To achieve this, 
we conducted four studies with the following aims: 
Paper I 
- To determine the incidence of Parkinson’s disease in Norway and establish a 
representative cohort of patients with early PD for longitudinal investigations. 
- To explore gender differences in the risk of PD and in clinical characteristics 
of early, untreated PD.  
Paper II 
- To describe the prevalence and severity of autonomic and sensory symptoms in 
a representative cohort of patients with early, drug-naïve PD. 
- To identify clinical and demographic factors which interfere with autonomic 
and sensory symptoms in early, untreated PD. 
Paper III 
- To determine the influence of dopaminergic treatment on autonomic symptoms 
in early and previously untreated PD. 
Paper IV 
- To identify the factors contributing most to impaired quality of life in early PD. 
- To determine if quality of life in patients with early PD is most affected by 
motor or non-motor symptoms.  
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3. Patients and methods 
The here presented work was part of the Norwegian ParkWest study which was 
established to study the clinical course and neurobiology of Parkinson’s disease in a 
representative cohort of patients. The study was approved by the Regional Committee 
for Medical Research Ethics, University of Bergen. 
All investigations were performed by study physicians and/or study nurses in an 
unblinded setting, using either direct interview or scoring based on examination. 
3.1 Base population and case identification 
We aimed to recruit all cases of incident Parkinson’s disease between 1st November 
2004 and 31st August 2006 from a base population of about 1 052 000 inhabitants. 
The study area comprised four counties, and all five neurological departments from 
those counties participated. All these study centres are responsible to provide second-
line neurologic health care for geographically determined regions which together 
cover the study area. Cooperation with the only neurologist exclusively practicing 
outside the participating hospitals was established.   
According to the Norwegian Medicines Agency’s regulations and guidelines, patients 
with suspected Parkinson’s disease or other parkinsonism are to be referred to a 
specialist in neurology for diagnosis and initiation of treatment. This is incorporated 
in practice, as also indicated by a nationwide survey from 2006.379  
To ensure a case identification as complete as possible, we applied the following: 
1. All hospital departments, general practitioners, consulting physicians of 
nursing homes, geriatric care centres and other institutions for persons of older 
age were informed about the study by mail or email before and during the 
study period. 
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2. All referral letters to the participating study centres were hand searched for 
symptoms possibly representing formerly not diagnosed parkinsonism. 
3. Hospital databases were screened electronically for patients diagnosed with PD 
for the first time during the screening period and for 3 months after (to capture 
delays in coding). 
4. Six months after the end of the screening period, a random sample of the study 
population from Hordaland county, comprising 43 716 individuals, was 
performed by linkage to their general practitioners’ electronic medical record 
system. Records dating back to one year before study start were searched for: 
a. Written terms including “Parkinson”, “Parkinsonism”, “ParkWest” and 
the cardinal motor features of PD, 
b. disease codes used by practitioners and hospitals for PD, parkinsonism 
and other movement disorders,  
c. anti-Parkinson drugs including their trade names. 
Patient files with hit on at least one search item were completely screened by 
the author to determine whether the current case was correctly referred or not 
referred to the study. 
3.2 Diagnosis of Parkinson’s disease 
As the diagnosis of PD is challenging in the early phase, especially when 
dopaminergic treatment has not yet been applied, the diagnostic procedure comprised 
several stages: 
1. Initial screening visit 
All individuals identified with possible incident parkinsonian symptoms were 
examined by study neurologists. Based on broad provisional diagnostic 
criteria, an initial study diagnosis was given: 
a. Incident PD (study-inclusion when consent given)  
b. Uncertain PD (later re-assessment) 
c. No PD (routine follow-up) 
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2. Baseline assessment  
Individuals with incident PD that consented to participation were investigated 
according to the study protocol. Those without consent were invited to routine 
follow-up for clinical re-assessment. Patients with initially uncertain PD that 
were later diagnosed with PD were then offered study-inclusion. 
3. Follow-up  
Patients who participated in the study underwent follow-up twice per year with 
evaluation of clinical development and therapy response.  
4. Final determination of the diagnosis  
After at mean 28 months from the initial screening visit, all available 
information from clinical notes, study protocols and radiological examinations 
were evaluated by two study neurologists (GA and JPL). The clinical 
diagnostic criteria provided by Gelb in 1999 were applied to determine a 
diagnosis of possible or probable PD.31 The diagnosis of other parkinsonian 
conditions was based on the respective diagnostic criteria.108,109,130,205,380
A flowchart demonstrating the diagnostic evaluation process is shown in Figure 1, 
page 853 of paper I. 
3.3 Definition of incidence 
Cases were defined as incident PD if 
- they had for the first time been referred to a specialist in neurology for possibly 
Parkinson-related motor-symptoms within the study period, 
OR 
- parkinsonism had explicitly been suspected by a physician for the first time 
within the study period, 
AND 
- they were finally provided with a diagnosis of Parkinson’s disease by a study 
neurologist. 
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3.4 Control group 
A control group was primarily recruited from among the patients’ spouses or friends, 
excluding sib family members. A lower number of controls were recruited from clubs 
for elderly and similar organizations. Of the 205 recruited controls, subgroups 
matched for age and gender to the investigated patient group were included in the 
studies for paper II and IV. 
3.5 Assessment of motor symptoms and disease severity 
Motor symptoms of PD were assessed with the UPDRS,157 which has become one of 
the most widely used scales to investigate the presence, severity and development of 
symptoms related to Parkinson’s disease. It consists of 42 single items which cover 
information on neuropsychiatric disturbances in part I, activities of daily life in 
addition to sensory disturbances in part II, examination-based motor function in 
part III, and complications from therapy as fluctuation and dyskinesia in part IV. 
Ratings range from 0 to 4 with higher scores indicating higher severity.  
To assess the pattern of parkinsonism in paper I, mean scores for the motor domains 
tremor, rigidity, bradykinesia and axial impairment were calculated based on the 
UPDRS part III according to Levy.381
For paper II, patients were classified into the motor subtypes PIGD, indeterminate, or 
tremor-dominant, using the UPDRS parts II and III as suggested by Jankovic.156
Based on clinical considerations and previous publications, we composed symptom 
variables for 8 motor symptoms for analyses in paper IV, using items from UPDRS II, 
III and IV.382,383 A variable for nocturnal motor symptoms was calculated from three 
items from the Parkinson’s Disease Sleep Scale (PDSS).384 Details of the composition 
of motor variables are listed in table 1, page 1028 in paper IV. 
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Disease severity was measured with the Hoehn & Yahr scale (HY),385 which is based 
on the uni- or bilateral presence of symptoms, the grade of postural instability and 
mobility. Scores range from 0 to 5, the highest score indicating that the individual is 
wheelchair bound or bedridden unless aided.  
To access activities of daily living, the Schwab and England scale was used.386 It rates 
the degree of independence from other persons to perform tasks of daily life. Total 
independence is indicated by score 100%, while 0% indicates a total dependent and 
bedridden individual. 
3.6 Assessment of non-motor symptoms 
Cognitive function (paper I and IV) 
Overall cognitive function was assessed with the Mini Mental State Examination 
(MMSE),387 which consists of 20 items on different cognitive domains. Scores range 
from 0 to 30, the highest indicating normal cognitive function, while a score of 25 or 
lower is recommended for the diagnosis of dementia in PD.388
Depression (paper IV) 
The Montgomery and Aasberg Depression Rating Scale (MADRS, 0-60) was used to 
explore depressive symptoms.389 It is an observer-based rating scale recommended for 
use in PD.390 The MADRS consists of 10 items, each ranging from 0 to 6 with higher 
scores for more severe symptoms. A score 20 was taken to indicate moderate or 
more severe depression.391
Apathy (paper IV) 
We assessed apathy with the Starkstein Apathy Scale (SAS), which consists of 14 
items, each rated on a four-point Likert scale, with a total range from 0 to 42 and 
higher scores indicating more severe apathy.392 It is recommended for use in PD with 
a cut-off of 13/14 to detect clinically significant apathetic symptoms.221
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Fatigue (paper IV) 
Fatigue ratings were obtained with the Fatigue Severity Scale (FSS). The 9 items 
range from 0-7 and a score of 4 or higher marks clinically relevant fatigue.393,394 The 
scale is recommended to assess the severity of fatigue in PD.394
Autonomic and gastrointestinal symptoms (paper II, III, IV) 
Autonomic symptoms were assessed with three different questionnaires, all with a 
range of 0-4 or 0-3, where “0” indicates the absence and the highest score indicates 
the most severe characteristic of a symptom: 
1. The UPDRS, range 0-4, for dysphagia and increased saliva/drooling. 
2. A preliminary version of the Movement Disorders Societies revision of the 
UPDRS (pMDS-UPDRS), range 0-4, for constipation, urinary urgency, 
lightheadedness standing, increased saliva/drooling, dysphagia.16 A score of 
“2” or more indicates that the severity of the respective symptom interferes 
with daily activities.  
3. A questionnaire created for the study, range 0-3, for constipation, urinary 
dysfunction, increased sweating (“ParkWest questionnaire”). 
The pMDS-UPDRS and “ParkWest questionnaire” are shown in appendix III. 
These questionnaires were applied on patients on all major study-visits. For controls, 
only the UPDRS and ParkWest questionnaire were applied at baseline.  
In paper II, frequency calculations of autonomic and gastrointestinal symptoms at 
baseline were based on the UPDRS and the ParkWest questionnaire as they were 
available from both patients and controls. Severity scores were based on the pMDS-
UPDRS as it provides reliable severity ratings based on a symptom’s impact on daily 
activities. Paper III and IV are based on information from the pMDS-UPDRS only. 
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Blood pressure was measured manually after 10 min supine and again after 2min 
standing (paper II and III). Orthostatic hypotension was defined as systolic blood 
pressure drop of at least 20mm Hg according to published guidelines.395
Sensory symptoms (paper II and IV) 
Sensory complaints as pain, cramping or other discomfort were in paper II assessed 
with one question from the UPDRS in patients and controls for its frequency, and 
with one question from the pMDS-UPDRS to access the severity in patients (paper II 
and IV). 
Olfactory function was tested with two odours (vanilla and coffee), presented for 
patients and controls in open, dark glasses, eyes had to be closed (paper II only). 
Failure to identify or precisely describe the characteristics of both odours was taken to 
indicate hyposmia.  
Sleep disturbances (paper IV) 
A diversity of sleep related problems were assessed with the Parkinson’s Disease 
Sleep Scale (PDSS), recommended for use in PD.384,396 Fifteen questions cover sleep 
quality, motor and non-motor nocturnal disturbances as well as daytime sleepiness. 
Each item ranges from 0 (not present) to 10 (severe and always present). As one of 
the aims in paper IV was to specifically compare the impact of motor vs. non-motor 
symptoms on quality of life scores, we calculated a separate sum score for nocturnal 
motor symptoms (PDSS items 9: urinary incontinence due to motor “off”; 
12: awakening in the morning due to dystonia; 13: tremor when awakening). Item 14 
(unexpectedly falling asleep during the day) was removed as daytime sleepiness was 
assessed separately (see below). The remaining 10 PDSS items composed a score for 
non-motor sleep disturbances. There is no consensus on a cut-off value for the PDSS, 
but a sum score of 100 or lower for the total PDSS has been used to indicate more 
severe sleep problems.397
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Daytime sleepiness was assessed with the Epworth Sleepiness Scale (ESS).398 The 
likelihood to doze off in eight daily situations is rated with a range from 0 (would 
never doze) to 3 (high chance of dozing), leading to a maximum score of 24. A cut-
off of 10/11 has been proposed to detect pathological daytime sleepiness.396
Details on the composition of non-motor variables for paper IV are shown in table 1, 
page 1028 in paper IV. 
3.7 Assessment of quality of life 
The Short-form Health Survey (SF-36) is a generic questionnaire, meaning it was not 
specifically developed for use in patients with PD and is thus applicable for healthy 
controls.399 It assesses the health status with 36 questions in eight domains with 
summary scores for physical and mental health aspects. The physical compound 
score, PCS (combined domains: physical functioning, role-physical, bodily pain, 
general health) and mental compound score (combined domains: vitality, social 
functioning, role-emotional, mental health) were calculated according to the 
published manual.400 Higher values indicate better quality of life and a score of 50 
represents the age-specific mean for a normative control population. The SF-36 has 
frequently been used in patients with PD, has shown good reliability and 
discriminative validity and is recommended for use in patients with PD.325
3.8 Medication 
Levodopa-equivalent daily dose 
For the symptomatic treatment of Parkinson’s disease, a number of pharmacological 
agents are used with different dopaminergic efficacy. To assess the impact of 
primarily dopaminergic medication on different symptoms, we calculated the 
levodopa-equivalent daily dose (LED) for each patient at the time of interest. For 
paper III, this calculation was based on a formula used in earlier publications:401,402
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LED = milligram (mg) standard Levodopa + mg sustained release Levodopa x 0,75 + 
mg Levodopa taken together with Entacapone x 0,25 + mg Ropinirole x 16.67 + mg 
Pramipexole (salt) x 67 [mg Pramipexole (salt) equate mg Pramipexole (base) x 1.4].  
In 2010, a systematic review on calculation of the LED in PD was published,403  and 
the recommended formula from this review was used in paper IV. For three drugs, 
this formula used higher factors compared to the calculations for paper III, leading to 
slightly higher LED for some patients: Entacapone x 0.33 vs. 0.25, Pramipexole x 100 
vs. 67 (salt), Ropinirole x 20 vs. 16.67.  
Non-PD medication 
Autonomic symptoms may be influenced by medication given for other conditions 
than PD. This was taken into account in paper III by registering non-PD medications 
and grouping the drugs with respect to the autonomic symptoms they may influence: 
Laxatives (constipation), cardiovascular acting agents (orthostatic hypotension and 
orthostatic dizziness), anticholinergics (sialorrhea and urinary dysfunction) and 
antidepressants (sialorrhea). Changes during the observation period were classified as 
potentially “increasing”, “decreasing” or “neutral” in relation to the respective 
autonomic symptom and implemented in one of the regression analyses as a covariate.  
3.9 Statistical analyses 
Data on the population size and distribution of age and gender in the study area by 1st
January 2005 were obtained from Statistics Norway, which provides official statistics 
about the Norwegian society (www.ssb.no). Crude incidence, age- and gender 
specific incidence rates and incidence rates corresponding to the 1991 European 
standard population were calculated. 
For comparison between independent groups, Ȥ2-test was used for proportions (paper 
I, II, III), Student’s t-test for means of approximately normally distributed data (paper 
I, II, III) and Mann-Whitney test for markedly skewed data (paper I, II). When 
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longitudinal results were compared, we performed McNemar test to assess changes in 
proportions (paper III, IV), paired samples t-test for changes of the mean in 
approximately normally distributed data (paper IV) and Wilcoxon signed ranks test 
for changes of the mean in markedly skewed data (paper III).   
In paper II, a linear regression model was used to assess the relationship between the 
number of autonomic and sensory symptoms and different covariates. A logistic 
regression model identified risk factors for the occurrence of different autonomic or 
sensory symptoms. 
In paper III, the association between changes in severity scores of autonomic 
symptoms and the daily levodopa-equivalent dose (LED) was tested with an ordinal 
regression model. 
In paper IV, linear regression models were created to investigate the association of 
motor and non-motor variables with the physical and mental compound scores of the 
SF-36. Data from baseline and three years later were analysed separately in three 
main steps with increasing interaction of the included variables: 
- In step 1, one regression model was run for each motor and non-motor variable 
with the SF-36 compound scores as dependent variable, corrected for age, 
gender and education.   
- In step 2, the regression procedures were performed with either all motor 
variables or all non-motor variables included in the same model, to reduce the 
impact of covariance.  
- In step 3, all motor and non-motor variables were included in the same 
regression models. 
For the regression models in step 2 and 3, a stepwise backward procedure eliminated 
those variables not contributing relevant proportions to the current regression model 
(criterion: probability of F-to-remove 0.1). The proportion of variance of the SF-36 
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compound scores explained by the variables finally included in the models was 
calculated (R2). 
Statistical analyses were performed using SPSS versions 14.0-17.0 and 20 (SPSS, 
Chicago, IL) in addition to R 2.6.1 (paper I only).  
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4. Summary of results 
Paper I 
Paper I revealed an annual crude incidence of Parkinson’s disease in western and 
southern Norway of 13.7 cases per 100 000 inhabitants per year, with a maximum for 
the decade 70-79 years of age. Adapted to the European standard population, the 
incidence rate was 12.6/100 000, with a clear male preponderance (male to female 
ratio 1.58 (CI 1.22-2.06)), which was present in all age groups. Electronic screening 
of general practitioners’ medical records of a subpopulation identified no cases 
missed to referral. The clinical onset of PD was slightly later in woman compared to 
men (68.6 vs. 66.3 years, p=0.062), but measures of motor dysfunction, disease 
severity, disability and cognitive impairment were similar in men and women at the 
time of diagnosis. 
Paper II 
In paper II we found that autonomic and sensory symptoms were more frequent in 
patients with PD already at diagnosis when compared to controls matched for age and 
gender (2.9 vs. 1.1 out of 8 assessed symptoms, p<0.001). Most frequent in patients 
were reduced olfaction (59%), urinary problems (47%), increased saliva/ 
drooling (42%), constipation (39%) and sensory complaints (34%). The majority of 
patients (58%) were not impaired in their daily activities by any of these symptoms, 
and less than 10% reported a moderate or severe affection of their daily activities. 
More severe disease at diagnosis (Hoehn & Yahr stage) and the PIGD motor subtype 
were associated with a higher number of autonomic and sensory symptoms. 
Gastrointestinal symptoms and abnormal sweating were more frequent in more 
severe PD. 
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Paper III 
In paper III we found that dopaminergic treatment of patients with early PD affects 
the presence and severity of autonomic symptoms only slightly. In the group of 
patients that used dopaminergic treatment one year after baseline (82%), constipation 
and orthostatic blood pressure drop increased. We observed also a tendency towards 
increased orthostatic dizziness and urinary dysfunction. Mean dysphagia scores were 
reduced after the initiation of dopaminergic treatment, and this was associated with 
higher levodopa-equivalent daily doses. No significant changes in autonomic 
symptoms were found in patients not treated with dopaminergic agents. 
Paper IV 
In paper IV we showed that health-related quality of life is reduced already from the 
time of diagnosis in patients with early PD. The non-motor symptoms with most 
impact on HRQoL-measures were depression, fatigue and sensory complaints, while 
the most important motor symptoms were gait disturbances and problems to perform 
daily activities for personal needs (cutting food, dressing, hygiene, turning in bed).  
Overall, the variance of both physical and mental quality of life sum-scores from the 
SF-36 was to a higher proportion explained by non-motor symptoms than motor 
symptoms, both at diagnosis and three years later. This was true both when motor and 
non-motor symptoms were analysed in separate regression models and when they 
were included in the same model.  
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5. Methodological considerations 
5.1 Epidemiological issues 
Investigation of incidence 
The estimation of incidence figures relies heavily on the methodology applied, and 
our study followed to a large extent proposed scientific criteria:68
1. The base population and observation time are recommended to cover about one 
million patient years, which was exceeded in our study observing a population 
of about 1 million for 20 months. Due to the multi-centre approach, this 
population size was feasible to access. 
2. The prospective approach ensured higher case ascertainment and data accuracy 
compared to retrospective methods. 
3. We applied multiple sources of case identification to achieve as complete case 
ascertainment as possible. To verify this, an electronic search of the medical 
databases of urban and rural located general practitioners was performed in a 
subarea, but identified no cases of possible PD that had not been referred to the 
study. It is likely that the structure of the health-care system in Norway has 
contributed to this effective case ascertainment. Alternatively, a population 
screening for cases might have revealed additional cases, but was not feasible. 
It would also have detected cases in much earlier stages of PD, before the 
individuals seek health care, what could have led to an overestimation of the 
incidence-rates.  
4. All patients referred for symptoms possibly representing parkinsonism were 
examined by study neurologists, ensuring proper diagnosis. 
5. We defined the time of incidence by the date of diagnosis, which is considered 
the most practical approach. However, the risk of underestimation due to cases 
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that die before they have received the diagnosis may represent a minor 
confounder of incidence figures. 
6. We used clear and consistent inclusion and exclusion criteria. 
7. Follow-up improved diagnostic accuracy and the final diagnosis was set only 
after at mean 28 months of observation. That implies that some individuals had 
a shorter follow-up time, and single cases had not yet started with 
dopaminergic medication, meaning a risk for an incorrect diagnosis of PD was 
still present. 
8. We reported incidence rates by standard age strata and the overall incidence 
adjusted to the 1991 European standard population, to enable comparison 
between studies. 
Establishment of a representative cohort 
To study clinical and biological aspects of a heterogeneous disease like PD, it is 
preferable to establish a cohort of patients as unselected as possible. Population-based 
studies are in this respect superior to clinic-based studies as the latter are likely to 
accumulate more severe, complicated and younger cases. Out of the 265 individuals 
we identified as having PD, a high proportion (80%) consented to further 
participation in the study and follow-up. The mean age of 68 years (range 42 to 88 
years) reflects the typical older population affected by the disorder.68 The anamnestic 
duration from the first PD-associated symptoms of 2.3 years corresponds to the 
usually observed and reasonable delay between the first occurrence of abnormalities 
and the diagnosis of PD. Thus, we are confident of having based our findings on a 
best possible unselected and therefore representative cohort of patients with early PD. 
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5.2 Assessment tools 
The results of clinical studies depend on the tools used for assessment, and the studies 
in this thesis are to a large extent based on recommended scales and scores for the 
respective conditions. Due to lacking availability or practical issues, single symptoms 
were assessed with not or not fully established methodology.  
Autonomic and sensory symptoms 
The use of three different scales to assess autonomic and sensory symptoms was 
suboptimal. However, the now established and validated SCOPA-AUT, NMSS and 
NMS-Quest14,15,404 were not available when this study was planned, and the 
COMPASS405 was considered much too time consuming. We considered therefore the 
pMDS-UPDRS suitable to assess the severity of autonomic and sensory symptoms, 
what was supported by the later validation of the final MDS-UPDRS part I for 
assessment of non-motor symptoms in PD.406 As it was not applied in the controls, the 
UPDRS and “ParkWest” questionnaire were used in combination to assess the 
frequency of autonomic and sensory symptoms in patients and controls. These scales 
have not been validated for the assessment of autonomic symptoms in PD. They 
provide, however, a meaningful and similar grading of symptom-severity, in the 
pMDS-UPDRS related to a symptoms impact on daily activities. An advantage was 
the application by interview, which likely has limited misinterpretation.  
Olfactory dysfunction 
Testing of olfactory dysfunction was limited to the identification of two odours, 
which is a more simple method compared to more sophisticated assessments of 
olfaction with odour-batteries as “Sniffin’ sticks”407 or University of Pennsylvania 
Smell Identification Test (UPSIT).408 However, our results are in range of earlier 
prevalence figures of olfactory dysfunction in both patients (59% in our study vs. 45-
90% earlier)102 and controls (21% vs. 25%).284 A recent study found about 45% of PD 
patients being anosmic and 51% hyposmic.282 Using a more complex odour-
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identification test may have revealed more hyposmic individuals also in our cohort, 
while we are confident to have identified the anosmic also with the test method we 
applied.  
Quality of life 
Quality of life was assessed with the SF-36, and statistical analyses were performed 
on the basis of compound scores for physical and mental HRQoL (PCS, MCS). As it 
has been shown that these two scores not necessarily reflect distinct measures of 
physical and mental health,409 we were cautious in our interpretations and took the 
summary scores as a whole to reflect the overall health-related quality of life. It has 
also been recommended to use the eight domains of the SF-36 as more specific 
quality of life measures,410 but this was not in accordance with the aim of paper IV 
and would have hampered the interpretation significantly due to a large number of 
results. 
5.3 Statistical procedures 
Statistical procedures are central and challenging elements of research which have to 
be chosen carefully for the specific data and questions assessed. The bivariate 
analyses and regression procedures performed in paper I-III represent standard 
practice for the respective problems investigated. The methodology used to determine 
the impact of motor vs. non-motor symptoms on quality of life measurements in 
paper IV is not established, but shows similarities to earlier publications.383,411,412 Two 
problems dominate this type of analysis. First, the relatively large number of 
explanatory variables in addition to confounding factors may reduce statistic power 
when all are included simultaneously. Second, a varying degree of interaction 
between clinical variables exists often and can affect the effect-size and power of 
results for covariant variables and overall results. We have taken this into account by 
increasing the interaction of variables in three steps, thereby also documenting the 
association of the single candidate variables with quality of life measures, only 
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corrected for demographic factors (regression step I). This was followed by increasing 
the amount of involved motor- and non-motor variables in each regression procedure 
through step II and III. The backward regression led to a limited number of variables 
that explain the variance of SF-36 scores best and present a stronger and more simple, 
final model. Despite the advantages of this approach, stepwise regression procedures 
have drawbacks. One is that the final model with its limited number of variables 
neglects the higher number of variables originally involved, why the fit appears to be 
better than it actually is. Another problem is that the final results depend on which 
variables are excluded early in the procedure. The significance of a variable may 
differ depending on which other, possibly covariant variables are part of the model at 
each step, what means that a variable excluded early in the procedure could have had 
more significant impact in a later step.  However, although we have not published this 
in the papers, we performed also forward regressions to control the reliability of the 
backward regression results, and ended up with similar results, supporting the 
presented data.   
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6. General Discussion 
6.1 Incidence of PD in Norway 
While prevalence-numbers for Parkinson’s disease in Norway have been available 
since 1995,127 the Norwegian ParkWest study was the first to provide incidence 
figures for the country. In paper I, we found a crude incidence of 13.7/100 000 with a 
corresponding number of 12.6/100 000 when adapted to the European standard 
population from 1991. These data are the result of a methodology based on 
recommendations for high quality incidence studies from 2003.68 By January 2014, 
we could identify five further incidence studies on PD, most published after our paper 
I, which followed a similar methodology.73-75,413,414
Figure 2: Incidence of PD in 5 European studies. Data matched for age and gender to 1991 standard 
European population. Respective overall incidence in parenthesis. 
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Figure (2) shows the standardized age-specific incidence figures of these studies and 
our own. The herein documented standardized incidence for the United Kingdom 
(UK), Sweden and Norway ranges from 11.5 to 15.8/100 000, while the Russian study 
found a much lower number of 8.4/100 000. Although biological causes for these 
differences cannot be excluded per se, methodological reasons seem more likely, 
including distinctions in health-attitude and health-care systems, which may have led 
to unequal accessibility of incident cases despite the efforts of the investigators.415,416
The incidence numbers of these latest studies are overall lower than those of the best 
studies published until 2001, which ranged from about 16 to 19/100 000.68 It has been 
shown that the diagnosis given in early parkinsonism needs to be changed within the 
first year in about 30% of patients.417 Increased focus on a correct diagnosis, 
including diagnostic re-evaluation after significant follow-up-time, may have 
contributed to exclusion of more cases in the later studies. However, these numbers 
document also that the improved methodological homogeneity not necessarily led to a 
closer range in the resulting incidence figures, even within a limited geographic area. 
An uncertainty of ±2-3 cases per 100 000 inhabitants may thus be as close as one can 
get to the “true” incidence numbers.   
On the other hand, an underestimation of the incidence cannot be excluded for our 
study. Despite the multiple sources of case ascertainment, complete case 
identification is difficult to achieve in a large base population. The fact that no 
additional cases were identified by electronic screening of a subpopulation suggests, 
however, that we may indeed have recruited all incident cases. Yet, identification and 
diagnosis of PD represents a special challenge in the oldest age group. PD symptoms 
may be taken to represent features of normal aging, vascular or other 
neurodegenerative parkinsonism,70 and cases in nursing homes may not come to 
primary care physicians for diagnosis.418 Research criteria may be too narrow to 
include all variants of the broad spectrum of clinical PD, and even in a series of 
pathologically proven PD, 10% had been diagnosed with another parkinsonism during 
lifetime.419 On the other hand, overestimation of the incidence of PD in the oldest age 
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groups is as well a risk. DLB, vascular parkinsonism and other tremor conditions are 
examples that led to changed diagnosis within one year of the initial diagnosis in 
another incidence study.417 In our study, dementia with parkinsonism (13%) and 
vascular parkinsonism (7%) were among the most frequent conditions diagnosed 
instead of PD. These diagnostic challenges may also be the basis for the diverging 
incidence numbers for PD in the population 80 years also reported in the latest, 
methodologically improved studies shown in figure (2). While we found a decrease of 
the incidence in this age group along with two other studies, two reports describe a 
further increase of the incidence. Studies focused on screening of elderly populations 
for PD have revealed considerably higher incidence numbers with continuous 
increase for those aged 80+, but the results are weakened by a lack of follow-up.420-422
Whether aging continuously increases the risk for PD throughout the whole lifetime 
remains therefore an open question.  
6.2 Gender-differences in incident PD 
We found a male preponderance for the incidence of PD throughout all age groups 
with an overall 58% increased risk for men vs. women after standardization. An 
earlier published meta-analysis reported a practically identical male to female ratio of 
1.57,72 and numbers in the above mentioned high quality incidence studies range from 
1.30 to 1.83.73-75,413,414 The anamnestic onset of PD symptoms was in our study 
slightlyޤ albeit not significantlyޤ later in women compared to men, in line with several 
earlier studies.68,73-76 While the lower incidence and later onset of motor symptoms 
may suggest a neuroprotective mechanism in women, we could not find evidence for 
differences concerning the severity or pattern of motor features or overall cognition, 
also this consistent with other reports on incident or early PD.73,74,78 One imaging 
study on previously untreated PD patients has also documented a similar progression 
rate of dopaminergic degeneration and deterioration of motor function for both 
genders.76 Although a neuroprotective effect of oestrogens has been suggested from 
in vitro studies,85,86 this has not been confirmed in clinical trials,88,90 and the risk for 
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PD is furthermore similar in Asian women and men.68 These and our findings seem 
therefore to indicate that at least European women have a lower susceptibility to get 
PD compared to men, but the underlying cause remains uncertain. We found no 
evidence for a presence of disease-modifying or neuroprotective mechanisms in 
women, at least within the first time after the disease has become clinically overt. 
6.3 Non-motor symptoms in early PD 
6.3.1 Frequency and severity of autonomic and sensory symptoms 
Despite increasing recognition of non-motor symptoms as key-features in PD, their 
interference with quality of life and their development often before the onset of motor 
symptoms, autonomic and sensory symptoms are poorly investigated in the early 
stages of the disease. We have investigated the frequency and severity of these 
symptoms in a representative population-based cohort of 212 patients with incident 
PD. The often suggested influence of dopaminergic drugs on autonomic symptoms 
was avoided by examination prior to the initiation of PD-specific treatment. 
Furthermore, as autonomic problems also increase with higher age,423 we compared 
the frequency figures to a control group matched for age and gender.  
Paper II confirmed impaired olfaction as the most common non-motor symptom also 
in early PD, present in 59% of patients. Earlier reports have shown even higher 
frequencies (75 to 90%) but included more advanced disease stages and used more 
advanced tests.51,102 It is not clear whether olfaction deteriorates with progression of 
PD.52,288,289 If that was the case, it could explain higher frequencies for later stages. 
However, we could not find an association of olfactory dysfunction with age, disease 
severity or disease duration, in line with the general assumption that the olfactory 
deficit is rather stable in PD.283,289 As explained in “methodological considerations”, 
we may have failed to identify a number of patients with milder hyposmia, what may 
also have influenced our results.282
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After impaired olfaction, the most frequent autonomic and sensory disturbances were 
urinary dysfunction (47%), increased salivation/drooling (42%), constipation (39%), 
and sensory complaints (34%), while increased sweating (22%), dysphagia (19%) and 
orthostatic hypotension (18%) were not as frequent. All symptoms, with the exception 
of increased sweating, were much more frequent than in the control-group, what 
supports PD as the underlying cause. 
Figure 3: Frequency of autonomic and sensory symptoms and signs in patients at diagnosis vs. 
controls. 
At the time of publication of paper II in 2010, comparable reports were lacking, but 
some further studies assessing multiple non-motor symptoms in early stages of PD 
have been published by now. The frequency numbers we reported have been largely 
confirmed by a population-based study from northern England424 and a clinic-based 
study from China reporting on patients with a PD duration <2years.425 However, two 
Italian, clinic-based studies on overlapping cohorts of early, drug-naïve PD patients 
found clearly lower numbers.426,427 The mean age of patients was similar to our study 
in the English cohort, but lower (58-61 years) in the clinic-based studies, confirming 
81
the known selection-bias connected to this recruitment-form. All these four studies 
used one of the validated, self-report non-motor screening questionnaires 
NMSQuest424,426,427 and NMSS,425 what seems to indicate that our assessment 
methods were sufficiently reliable.  
Interestingly, our frequency figures also meet the range of earlier reports which 
included considerably later stages of PD,404,428-430 what may indicate that autonomic 
and sensory symptoms mainly emerge during the very early stages of PD. This would, 
however, be in some contrast to the findings in the above mentioned, large Chinese 
study, which assessed non-motor symptoms in patients with a PD-duration of 2-
5 years, 5-10 years and 10 years, respectively.425 Constipation, urinary problems, 
dysphagia, drooling and increased sweating occurred all significantly more frequent 
with longer disease duration, while orthostatic dizziness and pain did not.  
In the same study, Guo et al. have also documented increasing severity of non-motor 
symptom scores with longer duration of PD,425 in line with the general perception. To 
our knowledge, the severity parameters of non-motor symptoms have not been 
formally assessed in other studies on early PD so far. In our study, the severity of 
autonomic and sensory symptoms was overall low at diagnosis, although for each 
symptom, 8-18% of patients reported a severity with at least a slight impact on daily 
function. This underlines the need to assess these symptoms already from the earliest 
stages of PD, especially as patients tend to underreport non-motor symptoms if not 
specifically asked about them under their medical consultation.192
The high frequency of increased salivation or drooling already at diagnosis was 
unexpected, as this has not been reported earlier. Our finding was, however, recently 
confirmed when even 56% of 159 patients with newly diagnosed PD reported 
sialorrhea in an English incidence-cohort.424 Considering the high frequency in 
patients at diagnosis, especially in contrast to the very low frequency in age-matched 
controls, increased saliva or drooling could be considered a supportive feature for the 
diagnosis of PD, in line with reduced olfaction. However, drooling occurs also in 
MSA,431 and analysis of the saliva composition could be a more specific marker for 
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PD.279 Further studies on these issues will be needed to determine the diagnostic value 
of salivatory changes, possibly also for the identification of individuals at risk to 
develop motor-PD.  
The PIGD-subtype of PD has, in addition to neuropsychiatric and sleep problems, in 
single studies also been associated with an increased risk for orthostatic 
hypotension165 and drooling.424 In our material, the PIGD subtype was associated with 
constipation, and patients with PIGD had, in line with a later published study on early 
PD,424 overall a higher number of autonomic and sensory symptoms compared to 
those with tremor-dominant PD, already in this early stage of PD. Additionally, also a 
higher HY stage was associated with more autonomic symptoms, similar to findings 
in patient populations covering later stages of PD.432As axial symptoms are key-
features for classification into higher HY-stages and the PIGD subtype, common 
elements in the underlying pathophysiology of early axial and autonomic symptoms in 
PD can be suggested. The PIGD subtype is associated with higher cortical load of 
Lewy bodies,167,168 a different pattern of striatal dopaminergic activity169 and 
pathology in extranigral midbrain structures.433 This may indicate an overall more 
aggressive, or more widespread pathology in patients with early PD and axial 
symptoms, making them more likely also to develop more autonomic or other non-
motor features.  
6.3.2 Autonomic symptoms and dopaminergic treatment
Dopamine is involved in both central and peripheral mechanisms of autonomic 
regulation, but the influence of dopaminergic treatment on autonomic function is a 
matter of ongoing discussion and conflicting evidence.  Colonic transit-time is 
increased in PD,263,434 and this may be potentiated by dopaminergic treatment,435 but 
findings differ.436,437 Orthostatic hypotension in PD is caused by impaired cardio-
vascular response to postural changes, and several studies suggest that dopaminergic 
treatment facilitates the problem.438-440  The basal ganglia are involved in regulation 
of micturition, partly based on dopaminergic signaling.441 However, both 
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improvement and worsening of urinary symptoms related to dopaminergic treatment 
have been reported.252,442  
In paper III, we found only slight changes in autonomic symptoms after the initiation 
of dopaminergic treatment. Significant changes were observed for increased severity 
of constipation and orthostatic blood pressure, while slight worsening with 
borderline-significance was observed for urinary dysfunction and lightheadedness 
standing. Our results support in principle similar findings from two studies that 
investigated untreated patients with de novo PD 3 months and 2 years after baseline, 
respectively. In one of the studies,242 light-headedness was the only autonomic 
symptoms that increased after dopaminergic treatment, in the other study, only 
constipation tended to increase, but non-significantly (p=0.092).426 Although the 
observed changes were small, they seem to support the view that dopaminergic 
mechanisms may contribute to autonomic symptoms, and that this is to some degree 
also true in early PD. 
Interestingly, we found a tendency to improved dysphagia in our patients, which was 
significantly correlated to higher LED. Although dysphagia is often labelled as non-
responsive to dopaminergic treatment,443,444 at least partial improvement has been 
reported following levodopa, apomorphine and stimulation of the subthalamic 
nucleus.445-447 The conflicting evidence may reflect the unequal pathophysiological 
mechanisms contributing to dysphagia, with probable unequal responsiveness to 
dopaminergic stimulation. However, our data lend support to a recent publication 
suggesting that dysphagia at least in a proportion of patients can respond to increased 
dopaminergic treatment, and clinicians should be encouraged to try this in patients 
with dysphagia to reduce the risk for severe complications of aspiration.376
Despite these signs of some improvement in dysphagia, excess saliva or drooling was 
not reduced after the initiation dopaminergic treatment. A possible explanation may 
be that the clinical improvement in dysphagia did not include the mechanisms that 
actually account for the leakage of saliva from the mouth, as facial mimics, mouth 
opening and tongue motility.274,280 Alternatively, the stimulatory effect of levodopa 
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may have increased the production of saliva in a number of patients,278 and thus 
antagonized the positive effect of improved dysphagia. A closer analysis of the 
association between dysphagia, drooling and changes due to dopaminergic treatment 
also in the current cohort could shed some light on this interesting complex, but was 
not part of the present study.   
In line with two studies on initially untreated patients,242,426 findings for autonomic 
symptoms were similar in patients treated with levodopa and dopamine agonists, what 
is in some contrast to a Cochrane review from 2008 that concluded with a higher risk 
of constipation for treatment with dopamine-agonists compared to levodopa.448
Furthermore, larger cross-sectional studies have described an association of higher 
LED with an increased number or severity-score of autonomic symptoms.449,450 We 
could not reproduce this finding in our study, and it may reflect increased severity of 
the primary disorder in patients with higher levodopa-dosages rather than a dose-
dependency of autonomic side-effects of dopaminergic drugs, as an association 
between the severity of dysautonomia-scores and HY-scores has also been shown, 
including in paper I.449
The relatively low dose of dopaminergic treatment used in our study (mean LED 251 
±140) may have contributed to the limited changes observed in our cohort. This 
hypothesis is, however, not supported by the two above mentioned studies on initially 
untreated patients, which reported similar findings despite higher LED in their 
patients (376±183 and 356±169, respectively).242,426
Although the overall changes in autonomic symptoms after dopaminergic treatment 
were very limited in our study, individual responses on dopaminergic treatment may 
spread largely from clear improvement to problematic deterioration, masked in the 
analysis of mean values. Winge has for example in 2004 concluded that urinary 
dysfunction can improve, deteriorate or remain unaffected by dopaminergic treatment, 
but the individual response is unpredictable.256 Analysis of sub-groups of patients by 
type of response to dopaminergic treatment would be of relevance and interest in this 
respect, but was beyond the scope of the current studies.  
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6.4 The symptoms’ impact on quality of life in early PD 
Paper II has documented a frequent presence of several autonomic and sensory 
symptoms in early PD, but with overall low severity. It is widely accepted that non-
motor symptoms have considerable impact on quality of life in mid- and later stages 
of PD, but their importance for the quality of life in early PD has been largely 
neglected. Reduced quality of life in PD has been variably associated with longer 
disease duration, increased disease severity (Hoehn & Yahr stage) and higher daily 
levodopa dosages.326,327,451,133 This raises the question of when the disease actually 
starts to impair the quality of life of affected patients. Three reports on clinic-based 
patient groups with early PD are available.161,332,333 Although they did not compare 
quality of life measures in patients to normative values or control-groups, their 
findings suggest reduced quality of life already early in PD. We have in paper IV 
investigated 188 patients from our representative, population-based cohort with newly 
diagnosed PD with the generic SF-36 questionnaire and found the sum scores for 
physical and mental health-related quality of life (42.5±10.0 and 45.9±11.2, 
respectively) significantly reduced compared to normative population samples (50 for 
both, p<0.001). The reduction was also true for comparison to a control-group 
matched for age and gender (SF-36 physical: 51.1; SF-36 mental: 54.9, data not 
shown in paper IV). Our results thus extend earlier findings of reduced quality of life 
in patients with PD to be true already from the time of diagnosis, despite overall only 
slight or mild symptoms.  
We were interested to identify the factors that account for reduced quality of life in 
this early stage. For more advanced PD, a review from 2011 showed that the role of 
demographic parameters as age, gender and education is limited.133 Depression was 
the factor most frequently reported with impact on quality of life, and in most reports 
depression impairs quality of life more than other variables.131,132,333,451,452 Further 
frequent reported symptoms related to HRQoL133 were anxiety,132,453,454
fatigue,132,455,456 gait impairment132,457 and fluctuations132,458. Virtually all these earlier 
studies assessed only a limited selection of motor- and non-motor features, neglecting 
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possibly significant contributors to HRQoL, and produced therefore biased results. 
Patients with early, untreated PD have not been investigated in this respect, although 
the pre-medication state is of interest as a basis for longitudinal analyses and to 
indicate the consequences of the disease independent of treatment.  
To fill this gap, we have collected information on a wide range of motor- and non-
motor symptoms to study their independent impact on HRQoL in early PD, including 
the drug-naïve stage. Non-motor variables covered cognitive, autonomic, sensory and 
sleep-related problems, as well as mood-disturbances. 
We found the highest regression coefficient in our baseline-analyses for MADRS-
scores with mental SF-36 scores throughout all steps of the regression procedures 
(ȕ>0,5 for regression steps 1,2 and 3, all p<0.001). This complements earlier findings 
on advanced131,333,451,452 and late stages of PD132,459 and confirms the importance of 
depressive symptoms for quality of life throughout the whole course of the disease, 
including the time of diagnosis. Our findings do, however, probably also reflect the 
naturally strong interrelatedness of depression and quality of life, interestingly 
demonstrated in a recent study on the general UK population. Of 11 comorbidities 
investigated, including cancer, breathing problems and stroke, quality of life was 
lowest in people with depression.460
In contrast to depression, fatigue showed a solid correlation to the physical SF-36 
compound score at baseline. After 3 years, fatigue became the strongest contributor 
both to reduced SF-36 physical and mental compound scores. A clear impact of 
fatigue on quality of life in PD has been demonstrated in different studies455,456 and it 
is by many patients perceived as one of, or even the most disabling symptom.209 The 
question arises whether the predominant finding of depression as the most important 
contributor to reduced HRQoL is determined by the fact that most studies investigated 
depression, but not fatigue at the same time.131,383,451,452,461 However, also studies that 
have investigated both symptoms simultaneously found that depression was strongest 
associated to HRQoL, including one study on early PD.11,132,333,453 Methodological 
issues, including the applied assessment tools, may have contributed to the differing 
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findings in our study. Of importance may for example be that we report physical and 
mental SF-36 scores, as fatigue comprises both mental and physical fatigue, what is 
also reflected in the FSS-questions. In contrast, depression and the MADRS scale are 
heavily dominated by pure mental aspects. This inequality may have strengthened the 
impact of fatigue in the specific context of assessments in our study. Our results 
nevertheless underline the importance of fatigue for PD patients already in the earliest 
phase of the disease.  
Sensory complaints as pain affect quality of life both in the general population and in 
more advanced PD.11,296,460,462 We are only aware of one study that assessed the 
impact of pain on quality of life in early PD.161 The authors found a pain-prevalence 
comparable to our study, but no correlation to quality of life. This study assessed the 
presence/absence of pain, in contrast to the five-point severity rating in our study. The 
latter may have been more sensitive to detect a correlation with HRQoL-scores in the 
context of the overall low severity of pain (paper II). As also an association between 
pain and depression has been reported,463 covariance between those symptoms can be 
suspected. However, the significant contribution of pain to reduced physical SF-36 
scores in multivariate models, in contrast to depression which impaired mental SF-36 
scores, favours an independent role of pain for quality of life. 
Autonomic symptoms contribute to reduced quality of life in more advanced PD, but 
usually less than cognitive/psychiatric symptoms.11,12,132,464,465 Similar findings are 
reported from the only comparable study on early PD.161 One study that specifically 
focussed on urinary dysfunction in early PD, showed also only a minor impact on 
HRQoL, which increased with more severe PD-symptoms.466 In line with these 
reports, we found that the cumulative impact of constipation, urinary dysfunction and 
orthostatic dizziness on HRQoL was present, but mostly in bivariate analysis and 
negligible in multivariate analysis which included other non-motor symptoms, clearly 
ranging behind depression, fatigue and pain. Although we investigated only a 
selection of the autonomic symptoms associated with PD, especially constipation and 
urinary dysfunction are amongst those most frequently reported with impact on 
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HRQoL.11,132,464 We therefore think that our findings confirm the general perception 
and conclusions from paper II and III, that autonomic symptoms are of overall limited 
severity in early PD. 
Apathy, sleep problems, daytime sleepiness and cognitive impairment may have some 
impact on quality of life according to single reports on early PD,161,333,467 but these are 
infrequent findings. Our results confirm thus that these symptoms are of generally 
limited relevance for the quality of life in patients with early PD, although this may 
differ in single patients with severe problems.  
Postural instability, gait impairment and complications from therapy have been 
considered the most important motor symptoms for quality of life,131-133,468 but also 
axial symptoms, bradykinesia, rigidity and speech problems contribute in some 
studies.12,131-133,411 The best predictors of reduced HRQoL among the motor symptoms 
in our patients with early PD were impairment of gait and of the ability to conduct 
personal needs like dressing, eating, hygiene and turning in bed. This may at first 
appear surprising, as gait- and functional impairment are not pronounced in this early 
stage. However, a reduced ability to walk and perform personal needs threatens an 
individual’s independence, what may explain the strong impact on perceived quality 
of life. Axial symptoms also showed a high correlation in the first, simple regression, 
but not in the more complex multivariate models. This could be related to the known 
covariance of axial symptoms and gait problems,469,470 which may have erased the 
effect of axial symptoms when gait problems have been included in the same model. 
To our knowledge, only one study has earlier investigated the impact of specific 
motor symptoms on HRQoL in early PD.332 The authors reported axial impairment as 
the most important motor symptoms, but gait assessment was included in the sum 
score for axial impairment. Thus, our results specify and extend these findings and 
highlight the importance of gait impairment and impaired ability to perform personal 
needs for HRQoL in patients with early PD. The clinical impairment may appear 
mild, and patients may seem able to cope with these symptoms, but treating 
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physicians should take these two factors specific into account also for patients with 
very early disease. 
Figure 4: Proportions of the variance of SF-36 physical (PCS) and mental (MCS) compound scores 
explained by motor symptoms, non-motor symptoms, and both together. 
      
There are ongoing discussions as to whether motor or non-motor symptoms are more 
important for quality of life in PD.329,330 In available studies, mostly performed on 
patients with moderate or advanced disease, depression or a total non-motor symptom 
score have usually outranged the impact of motor scores.12,131,132,333,464 To our 
knowledge, only one former study has compared the impact of a wider range of 
specific motor and non-motor features of PD with respect to quality of life. The 
authors found depression slightly superior to ADL functioning as the best predictors 
of quality of life scores in patients with a mean PD-duration of 9 years.132  
We found that the variance of mental, but also physical SF-36 summary scores was to 
a larger extent explained by non-motor symptoms than motor symptoms. The results 
are consistent throughout the different steps of increasingly complex regression 
models and for analyses of both early, untreated patients and after 3 years follow-up. 
Our study is thus the first to document that non-motor symptoms predict quality of 
life in early PD better than motor symptoms when a wide range of both symptom- 
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categories is included in multivariate analyses. Furthermore, our results do not lend 
support to earlier suggestions that non-motor symptoms dominate in this kind of 
analyses only because they are less optimally treated compared to motor symptoms, 
and therefore relatively more severe.330 However, with longer duration of the disease, 
the complications of dopaminergic treatment and pronounced gait disturbances may 
increase the impact of motor symptoms, albeit also the load of non-motor symptoms is 
expected to increase.  
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7. Final conclusions 
The occurrence of PD in Norway is similar to other European countries, with a crude 
incidence of 13.7/100 000/year, corresponding to 12.6/100 000/year for the European 
standard population. The known male-preponderance of PD is also present in 
Norway, but significant clinical differences between genders lack at diagnosis. New 
evidence with respect to the underlying causes of the gender-related risk-disparities in 
PD was not found.  
Autonomic and sensory symptoms are frequent in untreated PD already at diagnosis. 
Although mild and with overall limited impact on quality of life, problems may be 
more severe in single patients, what the treating clinicians should be aware of. The 
initiation of dopaminergic treatment is unlikely to cause problematic autonomic side-
effects, at least when relatively low doses are used.  
The main factors leading to reduced health-related quality of life in early PD are 
fatigue and depression, but also gait disturbances, impaired ability to conduct personal 
needs and pain contribute. Overall, non-motor symptoms are more important for 
impaired quality of life in early PD than motor symptoms.  
Our findings underline the necessity to pay attention to non-motor symptoms already 
from the diagnosis of PD, although the consequences of motor-disturbances must not 
be neglected. In patients with dysphagia, dopaminergic treatment should be optimized 
as improvement may be achieved. Drooling should be further investigated with 
respect to its potential as a supportive diagnostic marker for PD or parkinsonism. 
Further incidence studies are needed to evaluate whether the currently available 
recommendations are sufficient to ensure homogeneous methodology, especially with 
respect to case-recruitment in the highest age-groups. 
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9. Appendices 
Appendix I 
Criteria proposed by the UK Parkinson’s Disease Society Brain Bank ( Hughes et al., 
JNNP 1992;55:181-184): 
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Appendix II 
Criteria proposed by Gelb (Gelb et al., Arch Neurol. 1999;56:33-39):
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Appendix III 
Non-motor symptom questionnaires 
ParkWest questionnaire (translated, original questions are in Norwegian): 
1. Are you constipated? 
2. Do you have problems passing water? 
3. Do you sweat more than usual? 
The answers were rated by the interviewer according to: 0=no symptom, 1=slight, 2=mild/moderate, 3=severe symptoms. 
Preliminary version of the Movement Disorder Societies revision of the UPDRS (pMDS-
UPDRS): 
1.8 Pain and abnormal sensory sensations - On the average during the past week,  
have you experienced pain and abnormal sensory sensations as a result of your  
PD? By “pain and abnormal sensory sensations”, I mean aching, cramping or other  
discomfort perceived by you to relate to PD and not to other medical conditions. 
0: None.  No pain or abnormal sensations. 
1: Slight.  Aching, cramping or discomfort, but without effect on daily activities. 
2: Mild.  Aching, cramping or discomfort occasionally interferes with daily activities. 
3: Moderate. Aching, cramping or discomfort often interferes with daily activities. 
4: Severe. Aching, cramping or discomfort interferes with daily activities to  
the point that it is a major contributor to overall disability. 
1.9 URINARY PROBLEMS – On the average during the past week, have you  
experienced urinary problems as a result of your PD? By “urinary problems,”  
I mean bothersome urinary frequency, urgency or incontinence. 
0: Normal. No urinary problems. 
1: Slight.  Occasional urinary frequency or urgency but no major inconveniences  
to normal activities. 
2: Mild.   Urinary frequency or urgency sufficient to cause inconvenience and requiring  
some adaptations in daily function, although no incontinence. 
3: Moderate.  Urinary frequency, urgency with occasional incontinence; significantly interferes  
with daily activities such as social functions. 
4: Severe.  Frequent urinary incontinence, may need to use catheter. 
1.10 CONSTIPATION IMPACT ON DAILY ACTIVITIES – On the average during  
the past week, have you experienced an impact from constipation on your daily  
activities as a result of your PD? By “an impact from constipation”, I mean a  
bothersome change in bowel habits, discomforts, and preoccupation with bowel  
movements and their impact on independence in daily activities. 
0: Normal.  No constipation. 
1: Slight.   Constipation present, but without impact on daily activities.  
2: Mild.   Constipation has mild impact on daily activities. 
3: Moderate.  Constipation causes significant discomfort or inconvenience that makedly  
impacts on daily activities 
4: Severe.  Constipation dominates your concerns or you need physical disimpaction for  
handling constipation. 
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1.11 LIGHTHEADEDNESS ON STANDING – On the average during the past week,  
have you experienced lightheadedness on standing as a result of your PD? By “lightheadedness”, I mean the impact 
of dizziness on your balance and safety  
when changing position from lying to sitting and sitting to standing. 
0: Normal.  No lightheadedness. 
1: Slight.   Lightheadedness occurs with changes in posture but has no impact on  
performance of daily activities. 
2: Mild.   Lightheadedness occurs with changes in posture so that you return to a sitting  
or lying position to manage symptoms. No falls and no loss of consciousness. 
3: Moderate.  Lightheadedness occurs with changes in position and has been associated  
with at least one fall in the past week, but without loss of consiousness. 
4: Severe.  Lightheadedness occurs with changes in posture and has been associated with at  
least one episode of loss of consiousness over the past week. 
2.2 Handling saliva – On the average during the past week, have you experienced 
problems with handling saliva as a result of your PD? By ‘problems with  
handling saliva’ I mean the presence of excess saliva during the day and night  
and the dependence on handkerchiefs or tissues. 
0: Normal.  No problem. 
1: Slight.  Excess saliva with nighttime drooling. 
2: Mild. Excess saliva with minimal drooling during the day. 
3: Moderate. Excess saliva that causes daytime drooling, requiring frequent use  
of a tissue or handkerchief, specifically more than two times daily.  
4: Severe. Drooling requires constant use of tissue or handkerchief. 
2.3 Swallowing and chewing/manipulating food in mouth – On the average during  
the past week, have you experienced problems with swallowing and chewing or  
manipulating food in your mouth as a result of your PD? By ‘problems with  
swallowing and chewing or manipulating food in your mouth’, I mean ease of  
swallowing, presence of choking, time required to chew and swallow, and  
adaptations in food preparation in order to avoid choking. 
0: Normal. No problems 
1: Slight.  Some difficulty with swallowing but no choking or extra time needed to chew food.  
However, food is not cut or prepared in a special way for you to chew or swallow. 
2: Mild. Chokes but not daily, or expends considerable time and effort to chew  
food, but food is not cut or prepared in a special way for you to chew or swallow. 
3: Moderate. Daily choking or food needs to be cut or prepared in a special manner  
because of difficulty chewing or swallowing. 
4: Severe. Unable to obtain adequate nutrition without an alternative route for  
nutritional support (i.e. nasogastric tube or gastrostomy). 
